| Entries |
| Document | Title | Date |
|---|
| 20080200366 | Trimeric Peptides for Use in Treating Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 08-21-2008 |
| 20080200367 | Compositions and Methods for Treating Sleep Disorders - The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (CCK) receptor antagonists. | 08-21-2008 |
| 20080200368 | Peptide composition - There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein (MBP) peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods. | 08-21-2008 |
| 20080200369 | Trophinin-Binding Peptides and Uses Thereof - Disclosed herein are compositions and methods useful for promoting sperm motility, promoting embryonic stem cell formation, promoting trophoblast formation, or promoting neuronal growth. The compositions and methods are based on peptide sequences that bind trophinin, inhibit bystin-mediated arrest of epidermal growth factor (EGF) receptor, and promotes EGF receptor autophosphorylation. | 08-21-2008 |
| 20080200370 | METHOD OF TREATING DRUG ADDICTION USING DEXTRO-MORPHINE - The present invention relates a method of treating drug addiction in an individual by administering to the addicted individual a therapeutically effective amount of dextro-morphine capable of activating an opioid receptor. It is disclosed here that dextro-morphine is suitable for treating addiction to natural opiates, semi-synthetic opiates, fully synthetic opioids, and endogenous opioid peptides, as well as nicotine. | 08-21-2008 |
| 20080207483 | Methods and compositions for diagnosis and therapy of cancer based on hyper-mutated tumor genes - The present invention provides novel methods and compositions for the diagnosis and treatment of cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 08-28-2008 |
| 20080207484 | Hybrid Proteins with ErbB4 Extracellular Domain and Neuregulin Heparin-Binding Domain for Targeting - Polypeptides of the neuregulin (NRG) heparin binding domain (N-HBD) and nucleic acids coding therefor are disclosed. In particular, fusion polypeptides are produced that comprise, as a targeting structure, a N-HBD polypeptide, fragment, homologue or functional derivative and a protein to be targeted. This is fused to a polypeptide or peptide being targeted (Ptrg) to cell surfaces rich in heparan sulfate proteoglycans to either activate or inhibit interactions at tyrosine kinase receptors. A preferred fusion polypeptide comprises an N-HBD, a spacer and the extracellular domain of erbB4, one of several receptors signaled by NRG, which is potent NRG antagonist. Such products are used to treat diseases or conditions where either agonism or antagonism at tyrosine kinase receptors has beneficial effects, including cancer and a multitude of diseases of the nervous system. | 08-28-2008 |
| 20080207485 | Mhc Oligomer And Method Of Making The Same - The invention discloses MHC oligomers and methods for making the same comprising at least two functional MHC complexes having a peptide binding groove, each MHC complex having a peptide bound in the peptide binding groove of the MHC complex, wherein each peptide has a modification which allows highly specific oligomersation of the functional MHC complexes through a core structure. | 08-28-2008 |
| 20080207486 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 08-28-2008 |
| 20080207487 | MANUFACTURING PROCESS FOR THE PRODUCTION OF POLYPEPTIDES EXPRESSED IN INSECT CELL-LINES - The present invention provides a manufacturing method for polypeptides that are produced in insect cells using a baculoviral expression system. In one example, the insect cell culture is supplemented with a lipid mixture immediately prior to infection (e.g., one hour prior to infection). The polypeptides are isolated from the insect cell culture using a method that employs anion exchange or mixed-mode chromatography early in the purification process. This process step is useful to remove insect-cell derived endoglycanases and proteases and thus reduces the loss of desired polypeptide due to enzymatic degradation. In another example, mixed-mode chromatography is combined with dye-ligand affinity chromatography in a continuous-flow manner to allow for rapid processing of the insect-cell culture liquid and capture of the polypeptide. In yet another example, a polypeptide is isolated from an insect cell culture liquid using a process that combines hollow fiber filtration, mixed-mode chromatography and dye-ligand affinity in a single unit operation producing a polypeptide solution that is essentially free of endoglycanase and proteolytic activities. In a further example, the isolated polypeptides are glycopeptides having an insect specific glycosylation pattern, which are optionally conjugated to a modifying group, such as a polymer (e.g., PEG) using a glycosyltransferase and a modified nucleotide sugar. | 08-28-2008 |
| 20080207488 | Method for Detecting Peptides Comprising a Cross-B Structure - The invention relates to the field of compositions comprising a protein, more specifically to pharmaceutical compositions. More specifically, the invention relates to the detection and/or removal of conformationally altered proteins and/or molecules comprising a cross-β structure from a pharmaceutical composition or any of its constituents comprising a protein. The present invention discloses that unwanted and/or toxic side effects of pharmaceuticals are caused by proteins present in said pharmaceutical and adopting a cross-b structure conformation. The invention further discloses a method for detecting a protein and/or peptide comprising a cross-β structure in a pharmaceutical composition or any of its constituents comprising a protein, said method comprising, contacting said pharmaceutical composition or any of its constituents comprising a protein with at least one cross-β structure-binding compound resulting in a bound protein and/or peptide comprising a cross-β structure and; detecting whether bound protein and/or peptide comprising a cross-β structure are present in said pharmaceutical composition or any of its constituents comprising a protein. The invention further disclose methods for removing cross-β structures from a pharmaceutical composition and controlling manufacturing a pharmaceutical composition. | 08-28-2008 |
| 20080207489 | Use of CCN5 for treatment of smooth muscle proliferation disorders - The invention provides methods for treating a smooth muscle cell disorder such as asthma, vascular injury, persistent pulmonary hypertension in the newborn, pulmonary hypertension in adults, megaureter, pyloric stenosis, uterine fibroids, lymphangioleiomyomatosis (LAM), cervical incompetence, or cancer, and methods for assessing smooth muscle tissue remodeling in a mammal by expressing CCN5 in a smooth muscle cell of the mammal, or by contacting the tissue directly with CCN5. | 08-28-2008 |
| 20080214434 | Treatment of endothelial dysfunction in diabetic patients - A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL). | 09-04-2008 |
| 20080214435 | Novel Cancer Indications of Mannan-Binding Lectin (Mbl) in the Treatment of Immunocompromised Individuals - The present invention pertains to the use of subunits and oligomers of mannan-binding lectin (MBL) in prophylactic and/or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of the gastro intestinal system, the renal system and further subjects suffering from thyroid cancer and melanomas. Haematological cancers include leukaemia, lymphoma and myeloma. The immunocompromised condition of the individual may be due to a cancer disease as mentioned herein or the treatment of said cancer disease. | 09-04-2008 |
| 20080214436 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 09-04-2008 |
| 20080214437 | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases - Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of these therapies. Routes used for delivering polynucleotides encoding a natriuretic peptide, or, for example, siRNA that down regulates natriuretic peptide receptor include subcutaneous injection, oral gavage, transdermal and intranasal delivery routes. Compositions can include chitosan, chitosan derivatives, and chitosan derivative and a lipid. Transdermal delivery can use a transdermal cream. Intranasal delivery can use a dropper or an aspirator for delivery of a mist. Oral gavage delivers equivalent to oral delivery. Delivery permits cell and tissue specific targeting of gene therapies resulting in expression of a natriuretic peptide or down regulation of natriuretic peptide receptor. A variety of cancers, asthma and viral diseases can be treated therapeutically using the methods and compositions of the present invention. | 09-04-2008 |
| 20080214438 | Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content - The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction. | 09-04-2008 |
| 20080214439 | AMINO ACID SUBSTITUTED MOLECULES - The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein. | 09-04-2008 |
| 20080221011 | Targeting complement factor H for treatment of diseases - The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion. | 09-11-2008 |
| 20080221012 | Activatable Clostridial Toxins - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 09-11-2008 |
| 20080221013 | Neurobiological compositions - Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders using lynx compounds. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. | 09-11-2008 |
| 20080221014 | Method of Diagnosing and Treating Glioma - The present invention is directed to methods and compositions for the diagnosis, prognosis and treatment of glioma in mammals. | 09-11-2008 |
| 20080221015 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS AND MUTANTS THEREOF - The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals. The invention specifically includes mutants with altered Eph binding constants and selectivities. | 09-11-2008 |
| 20080221016 | CD25+ DIFFERENTIAL MARKERS AND USES THEREOF - The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25 | 09-11-2008 |
| 20080221017 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration - The invention concerns a pharmaceutical or cosmetic composition, characterized in that it comprises at least a compound for inhibiting Langerhans' cell migration, said active compound being selected in the group consisting of protein kinase C (PKC) inhibiting compounds, matrix metalloprotease (MMP) inhibiting compounds, and combinations thereof, and at least a pharmaceutically or cosmetically acceptable carrier. Said composition enables to inhibit considerably Langerhans' cell migration induced by the presence of an allergenic agent. | 09-11-2008 |
| 20080227683 | Compounds Having Antitumor Activity - Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances. | 09-18-2008 |
| 20080227684 | Small Molecule Inhibitors of PDZ Interactions - The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided. | 09-18-2008 |
| 20080227685 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 09-18-2008 |
| 20080227686 | Novel Peptides that Promote Lipid Efflux - Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are methods of detecting plaque in vessels using the labeled peptides of the present invention. | 09-18-2008 |
| 20080227687 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING TARGETED SINGLE-WALLED CARBON NANOTUBES - The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to single-walled carbon nanotubes (SWNT) to form a protein-SWNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound SWNTs with specific wavelength is then used to detect and destroy those cells to which the SWNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells. | 09-18-2008 |
| 20080227688 | Inhibition of viral replication - The present invention provides inhibitors of viral replication, and methods related thereto. In general, such compounds can be classified as peptidyl fluoromethylketones (PFMKs). The PFMK compounds may be used to partially or completely inhibit viral infection. In certain embodiments, Z-FA-FMK may be used to inhibit replication of a reovirus, such as a wild-type or attenuated reovirus, or a leporipoxvirus, such as myxoma virus. These compounds may be useful for controlling viral infectivity in vivo and/or in vitro. | 09-18-2008 |
| 20080227689 | Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1 - The invention provides methods and compositions for treating pathogenic immune and inflammatory disorders through inhibition of polypeptide GalNAc transferase 1 (ppGalNAcT-1) transferase activity. | 09-18-2008 |
| 20080234175 | Process for Designing Inhibitors of Influenza Virus Structural Protein 1 - Disclosed are methods and compositions useful in identifying inhibitors of influenza virus, such as influenza A and B virus. Also disclosed are methods for preparing compositions for administration to animals, including humans infected with or to protect against influenza virus. | 09-25-2008 |
| 20080234176 | MODIFIED PEPTIDES AND THEIR USES - A modified pro-α chain comprising a triple helix forming domain linked to at least an N-terminal domain, the N-terminal domain containing a polypeptide from at least part of a laminin glycoprotein or secretory leukocyte protease inhibitor. The pro-α chain may form part of a procollagen molecule that has the N-terminal domain retained. The procollagen molecule may be incorporated into collagen polymers, matrices and gels and be used for such applications as wound healing. | 09-25-2008 |
| 20080234177 | Targeting-enhanced activation of galectins - Lectin-binding proteins and their therapeutic use. In particular, described are the targeting and targeting-enhanced multimerization and activation of galectins. Provided is a galectin-conjugate including at least one galectin molecule conjugated to a non-galectin cell targeting means. Exemplary targeting means include targeting means able to bind EGP2, a pancarcinoma-associated cell surface target antigen, CD antigen, such as CD7 or CD38, or a TNF family member, such as TRAIL-R. The targeting means may comprise an antibody or a functional fragment thereof, such as a single chain variable antibody fragment (scFv). Also provided is the use of a galectin-conjugate for treating a disease, like cancer or an immune disorder, such as auto-immune disease, allergic disorder, auto-immune encephalomyelitis, arthritis, colitis, hepatitis, asthma, multiple sclerosis, transplant rejection, Graft-versus-host disease (GVHD) and/or inflammatory bowel disease. | 09-25-2008 |
| 20080234178 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE SYSTEM MEDIATED DISEASES - The present invention is directed to compositions and methods for treating immune system mediated disease. In particular, certain embodiments of the present invention use BH3 mimetic therapy as an efficacious treatment of the effector phase of RA wherein the compositions and methods of the present invention markedly reduce the level of the Bcl-2 antagonist protein Bim present in RA synovial tissue as compared to control patients. Therefore, the present invention involves restoring the function of Bim in order to ameliorate inflammatory arthritis. In connection therewith, systemic delivery of a peptide to the BH3 domain of Bim effectively inhibits the development of K/B×N serum transfer-induced arthritis which closely resembles the effector phase of RA | 09-25-2008 |
| 20080234179 | ORALLY DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING A DELIVERY AGENT IN MICRONIZED FORM - Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin. | 09-25-2008 |
| 20080242587 | FUSION PROTEINS BINDING TO VEGF AND ANGIOPOIETIN - The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component. | 10-02-2008 |
| 20080242588 | SYSTEM FOR SEIZURE SUPPRESSION - Systems, including methods and compositions, for seizure suppression, such as inhibition of epileptic seizures. In some embodiments, the methods may provide a screen for anti-seizure drugs. One or more compositions may be selected based on an ability to affect a response of biological cells to a change in extracellular pH and/or to affect an activity of at least one acid sensing ion channel (ASIC). Based on the one or more compositions selected, at least one drug candidate may be assayed for inhibition of seizure-like electrical activity and/or seizures. In some embodiments, the methods and compositions may, respectively, administer and provide an effective amount of PcTX1, a peptide derivative of PcTX1 amiloride, an amiloride derivative, or a combination thereof to a subject prone to seizures and/or having a seizure, in order to suppress seizure activity. | 10-02-2008 |
| 20080242589 | SYNTHETIC LIPID MIXTURES FOR THE PREPARATION OF A RECONSTITUTED SURFACTANT - The invention relates to reconstituted surfactants consisting of artificial phospholipids and peptides able to lower the air-liquid surface tension, more particularly to reconstituted surfactants comprising special phospholipid mixtures and artificial peptides which are analogues of the natural surfactant SP-C protein for the treatment of respiratory distress syndrome (RDS) and other diseases relating to pulmonary surfactant dysfunctions. | 10-02-2008 |
| 20080242590 | New Method 706 - The present invention relates fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein has the formula M-A, capable of degrading amyloid beta peptide at one or more cleavage sites in its amino acid sequence, wherein M is a protein component that prolongs the half-life of the fusion protein, and A is a protein component that cleaves the amyloid beta peptide. | 10-02-2008 |
| 20080242591 | METHODS OF REDUCING ANGIOGENESIS - The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis. | 10-02-2008 |
| 20080242592 | METHOD FOR CONTROLLING BODY WEIGHT IN ESTROGEN-INSUFFICIENT WOMEN - Disclosed are methods of controlling body weight in estrogen-insufficient women by administering compositions comprising (A) those dried fruit solids that inherently comprise flavonoids, hydroxycinnamic acids, and a fiber component of which at least about 20% by weight is soluble fiber, and (B) a soluble, indigestible oligosaccharide in addition to any soluble fiber inherently in the dried fruit solids. The dried fruit solids may also be characterized as those selected from dried plum, dried grape, dried date, or dried fig. Administration of dried fruit solids (e.g., dried plum solids) in combination with soluble indigestible oligosaccharides (e.g., fructooligosaccharides) are surprisingly effective in controlling body weight gain in estrogen-insufficient women. | 10-02-2008 |
| 20080248991 | Chitosan Containing Solution - The invention provides a composition comprising (i) chitosan, a salt or derivative thereof or a salt of a derivative thereof, (ii) a polyol-phosphate or sugar-phosphate salt, (iii) a plasticizer, and (iv) a therapeutic agent. Typically, the composition is a solution or suspension at ambient temperature but forms a gel at physiological temperatures. | 10-09-2008 |
| 20080248992 | Immunokine composition and method - A composition and method for preventing HIV infection of mammalian cells. One aspect of the invention relates to an anti-immunodeficiency virus immunokine capable of binding to a cellular protein in a manner that prevents HIV infection of that cell. The compositions can include either an active bioactive polypeptide, such as native cobratoxin, and/or an inactivated bioactive polypeptide, such as cobratoxin in which one or more of the native disulfide bridges have been prevented from forming. The term “immunokine” is used to refer to an inactivated bioactive polypeptide, whether inactivated by chemical, genetic, and/or synthetic means as described herein, with the proviso that a corresponding active bioactive polypeptides can be included where applicable (e.g., for in vitro use). | 10-09-2008 |
| 20080248993 | Modified Beta Thymosin Peptides - A composition including an oxidized or superoxidized methionine-containing beta thymosin peptide, isoform thereof, fragment thereof, isolated R-enantiomer thereof or isolated S-enantiomer thereof, other than racemic thymosin beta 4 sulfoxide, or a modified beta thymosin peptide, isoform or fragment thereof with an amino acid substituent substituted for at least one methionine of an amino acid sequence of a normally methionine-containing beta thymosin peptide, isoform or fragment thereof, and method for forming same. | 10-09-2008 |
| 20080248994 | Methods of using deacetylase inhibitors to promote cell differentiation and regeneration - A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as enhancing expression of muscle-specific genes in myoblasts. Administering a DI to a subject also can provide some prophylactic or therapeutic effect for inhibiting, preventing, or treating associated with a degeneration or loss of tissue. The DI can be administered to a subject as part of a pharmaceutical composition. | 10-09-2008 |
| 20080248995 | Modulation of PPARgamma2 gene promoter by FOXO1 - A method for detecting a modulator of transcription of a human PPAR gene promoter is provided, comprising contacting a candidate compound with a cell transfected with an expression vector containing a heterologous gene operably linked to a PPAR promoter and an additional expression vector containing the FOXO1 gene, and comparing the level of expression of said heterologous gene in the presence of the compound and in the absence thereof, whereby a modulator of transcription of the human PPAR gene promoter is identified. The PPAR gene promoter is preferably the PPARγ2 promoter, and the DNA-binding domain of the FOXO1 protein binds to a sequence encompassing the 63 to 323 bp region of the human PPARγ2 promoter, preferably the 270 to 310 bp region. | 10-09-2008 |
| 20080248996 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 10-09-2008 |
| 20080248997 | T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. | 10-09-2008 |
| 20080248998 | COMPOSITIONS FOR ORAL ADMINSTRATION OF ACTIVE PRINCIPLES REQUIRING MASKING OF TASTE - Composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 μm. | 10-09-2008 |
| 20080255025 | Protease inhibition - Proteins including engineered sequences which inhibit proteases are disclosed, including proteins having two or more engineered Kunitz domains, and uses of such proteins. | 10-16-2008 |
| 20080255026 | Glycopegylated Factor Ix - The present invention provides conjugates between Factor Ix and PEG moieties. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 10-16-2008 |
| 20080255027 | Purification of proteins - The present invention relates to a selectively soluble polymer capable of binding to a desired biomolecules in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and/or salt concentration and is rendered insoluble and precipitates out of solution upon a change in the process conditions. The polymer is capable of binding to the desired biomolecule (protein, polypeptide, etc) and remains capable of binding to that biomolecule even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered such as by elution and further processed. | 10-16-2008 |
| 20080255028 | Collagen Receptor I-Domain Binding Modulators - The present invention relates to a refined and detailed molecular model of the α2⊕1 integrin I-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially α2β1 integrin modulators. The present invention further relates to novel α2β1 I-domain modulators, which are of therapeutic potential. The present invention further relates to specific families of small molecule modulators interacting with collagen receptors, tetracyclic polyketides and sulfonamides. The present invention further relates to the use of such modulators for the manufacture of medicaments for thrombosis, inflammation and/or cancer | 10-16-2008 |
| 20080255029 | Neuroendocrine Tumor Treatment - A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug. | 10-16-2008 |
| 20080261861 | 2-Micron Family Plasmid and Use Thereof - The present invention provides a 2 μm-family plasmid comprising a polynucleotide sequence insertion, deletion and/or substitution between the first base after the last functional codon of at least one of either a REP2 gene or an FLP gene and the last base before the FRT site in an inverted repeat adjacent to said gene. | 10-23-2008 |
| 20080261862 | Materials and Methods for Modulating Signalling by Alpha-V Integring Molecules - It is disclosed that the αvβ5 integrin mediates the proliferative signal provided by CD23 to pre-B cells. The region of CD23 which interacts with αvβ5 has been defined, and found to interact with a site on the integrin distinct from that which binds RGD. The invention provides methods for disrupting the interaction between CD23 and αvβ5 and methods of screening for chemical entities capable of disrupting this interaction. | 10-23-2008 |
| 20080269103 | Diagnostic and Therapeutic Use of the Kcne4 Gene and Protein for Alzheimer's Disease - The present invention discloses the differential expression of the gene coding for KCNE4 protein in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject, is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the KCNE4 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed. | 10-30-2008 |
| 20080269104 | Methods For Enhancing the Quality of Life of a Growing Animal - The present invention provides methods for enhancing the quality of life of a growing animal by feeding the animal a quality of life enhancing amount of a composition comprising about 10% by weight protein, about 4% by weight fat, and about 0.05% by weight of at least one omega-3 polyunsaturated fatty acid. Enhanced quality of life is shown by an improvement in one or more characteristics selected from the group consisting of trainability, cognitive function, motor skills coordination or agility, retinal development, cartilage protection, maintenance of muscle mass, and skin and pelage quality. | 10-30-2008 |
| 20080269105 | Delivery of drugs - Formulations of drugs and crystalline side chain polymers to provide controlled and/or sustained release drug formulations. | 10-30-2008 |
| 20080269106 | Methods and Compositions for Diagnosis and Treatment of Disorders Involving Macrophages - The present invention discloses methods of identifying and treating diseases or disorders, particularly those relating to hormone receptors and their activities. The invention also discloses methods of screening for drugs that can be used to treat diseases or disorders. The invention is based, at least in part, on the discovery of the role of macrophages in development of certain cancers, such as prostate cancer and breast cancer. | 10-30-2008 |
| 20080269107 | Methods and Compositions for Treatment of Cancers with Hoxb4 - In some embodiments, without limitation, the invention comprises methods and compositions for the treatment of mammalian cancers, comprising the administration of HOXB4 protein and/or the overexpression of HOXB4 nucleotide sequence in order to induce apoptosis or otherwise decrease the survival of the target cancer cells. | 10-30-2008 |
| 20080274945 | Infant Nutrition With Protease Inhibitor - Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity. | 11-06-2008 |
| 20080280810 | PEPTIDES HAVING AFFINITY FOR BODY SURFACES - Peptides having affinity for a body surface are provided. The peptides comprise a body surface-binding peptide block and at least one charged, terminal peptide block. These peptides have enhanced affinity for body surfaces and deposit more rapidly onto body surfaces than peptides lacking the charged terminal groups. The peptides are used to deliver and/or to seal benefit agents to body surfaces, thereby providing enhanced durability. | 11-13-2008 |
| 20080280811 | Compositions and Methods for Treating Vascular Permeability - The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema. | 11-13-2008 |
| 20080280812 | HUMAN IMMUNOSUPPRESSIVE PROTEIN - A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. Also disclosed is a method of treating inflammation, using an effective amount of an HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells, but not from NCCIT embryonal carcinoma cells. T98G glioblastoma cells or THP-1 monocytic leukemia cells. HISP can maintain T cells in a quiescent G.sub.0/G.sub.1 state without lowering their viability. HISP loses activity when treated with heat, pH2, pH11, or mixed with trypsin or carboxypeptidase, but not with neuraminidase. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not bind to heparin-sepharose CL-B gel; or to albumin-binding resin Blue Sepharose, HISP is concentrated with YM10 ultrafiltration. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells. A method of treating inflammation comprises administering an effective amount of hNT neuronal cells. | 11-13-2008 |
| 20080280813 | COMPLEX DRUG DELIVERY COMPOSITION AND METHOD FOR TREATING CANCER - The present invention relates to compositions and methods for producing a complex drug delivery system which specifically targets cancer cells, has an increase in cellular uptake, is cytotoxic, and suppresses antiapoptotic cellular defenses. | 11-13-2008 |
| 20080287341 | TREATMENT OF VASCULAR ABNORMALITIES USING NANOPARTICLES - Vascular abnormalities in a patient are treated by administering a therapeutically effective amount of an agent that reduces angiogenesis. The agent comprises an vascular leakage angiogenic inhibitor and/or vascular leakage angiogenic inhibitor expression plasmid/vector encapsulated by a biocompatible nanoparticle. | 11-20-2008 |
| 20080287342 | Compositions Comprising Modified Collagen and Uses Therefor - The invention provides modified collagen and related therapeutic and diagnostic methods. | 11-20-2008 |
| 20080293617 | Implantable Putty Material - The present invention provides compositions for an implantable putty material for delivery of active compounds to a patient. More specifically, the present invention provides a material having a pH of between about 3 and 6 and possessing putty-like physical properties, wherein the composition of the material includes collagen and water. The present invention also provides a method for using the implantable putty material. | 11-27-2008 |
| 20080300163 | Modified Human Four Helical Bundle Polypeptides And Their Uses - Modified human four helical bundle (4HB) polypeptides and uses thereof are provided. | 12-04-2008 |
| 20080300164 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making - A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described. | 12-04-2008 |
| 20080300165 | Purposeful Movement Of Human Migratory Cells Away From An Agent Source - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 12-04-2008 |
| 20080300166 | Treatment of Melanoma with Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 12-04-2008 |
| 20080300167 | Patched genes and uses related thereto - Methods for isolating patched genes, including the mouse and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expression of patched is associated with the occurrence of human cancers, particularly basal cell carcinomas of the skin. The patched and hedgehog genes are useful in creating transgenic animal models for these human cancers. The patched nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene. | 12-04-2008 |
| 20080300168 | INHIBITION OF MIGRATION AND INDUCTION OF CELL DEATH BY THE TYPE II COLLAGEN AMINO PROPEPTIDES - The present invention provides combinations and methods for inducing cell death, inhibiting angiogenesis, and inhibiting cell migration. In particular, the present invention provides methods for inducing cell death in a cell expressing an αvβ3 and/or an αvβ5 integrin. | 12-04-2008 |
| 20080300169 | Development of Novel Antibiotic Alternatives - The present invention relates to two recombinant colicin expression systems, one utilizing a yeast expression system that produces a protein that is inexpensive to purify, and the other utilizing a plasmid expression system to be used as a probiotic culture. The recombinant colicins provide effective alternatives to conventional antibiotics and may be used to improve the efficiency of pork production, and the safety of its products. | 12-04-2008 |
| 20080305985 | Isosteric Transormation - A method of generating an isosteric structure of a polypeptide at least partially containing D-amino acids from 3D-coordinates and sequence information of an L-configurated precursor having an N-terminal amino group or substituted amino group, a C-terminal carboxy group or a carboxy derivative, a backbone and L-amino acid side chains, and comprising the steps of—at least partially replacing backbone CO groups with NH groups and vice versa,—while keeping the 3D-coordinates of the precursors L-amino acid side chains, the N-terminal amino group or substituted amino group and the C-terminal carboxy group or carboxy derivative fixed. | 12-11-2008 |
| 20080305986 | Multimers of Peptides - Described are compounds useful for trimerising chemical entities, methods of trimerising chemical entities, and trimerised entities. In one aspect, the entities are peptides. | 12-11-2008 |
| 20080305987 | Sex-specific regulation of aging and apoptosis - The invention provides anti-apoptotic agents and therapies and uses thereof. Specifically, the anti-apoptotic agents and therapies involve human Xist gene, Xist RNA, Xist gene product, and antagonists and small molecule mimics of these nucleic acids and proteins. | 12-11-2008 |
| 20080305988 | V-Like Domain Binding Molecules - The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD. | 12-11-2008 |
| 20080312127 | Host Cell Comprising a Vector for Production of Proteins Requiring Gamma-Carboxylation - The present invention relates a host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein requiring gamma-carboxylation and associated expression control sequences and a nucleic acid molecule encoding a vitamin K epoxido reductase and associated expression control sequences and a nucleic acid molecule encoding a γ-glutamyl carboxylase and associated control sequences. The invention further relates to a method of producing a protein requiring gamma-carboxylation in high yields. | 12-18-2008 |
| 20080312128 | Cellular Biomarker Antioxidant Assay and Uses Thereof - The invention encompasses cell-based systems comprising biomarkers that respond to oxidative stress (OS) in a quantitative manner, and methods of use thereof. The systems are useful for screening, identifying and testing antioxidant agents, combinations, and formulations thereof for preventing, treating, or reducing symptoms of conditions associated with oxidative damage to cells. The cell-based systems are useful for identifying effective new antioxidant agents and for optimizing antioxidant formulations for targeted therapeutic applications. One cell-based system utilizes RPE cells of the eye for identifying and optimizing antioxidant compositions effective for treatment of age-related conditions such as macular degeneration. The cell-based systems provide a convenient, inexpensive and physiologically relevant in vitro alternative to human population-based methods for testing efficacy of nutritional and pharmaceutical compositions comprising antioxidants. The invention further encompasses nutritional or pharmaceutical compositions targeting particular diseases such as AMD, formulated using methods as disclosed herein. | 12-18-2008 |
| 20080312129 | Use of Mas G-Protein-Coupled Receptor Agonists and Antagonists, as Apoptotic-Activity Modulators for Study, Prevention and Treatment of Diseases - The present invention is characterized by the use of Mas G-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for study, prevention and treatment of diseases. It is further characterized by the use of Mas G-protein-coupled receptor agonist and antagonists for modulation of the apoptotic activity involving alterations in the activity of the protein kinase B/Akt. Another characteristic of the invention is the use of Mas G-protein-coupled receptor agonists and antagonists, including the Ang-(1-7) peptide and its analogues, agonists and antagonists, either peptidic or non-peptidic, as modulators of apoptotic activity for study, prevention and treatment of degenerative diseases of organs and systems, as an auxiliary measure for organs transplantation, treatment with embryonic, non-embryonic stem cells, re-implantation of organs and tissues and other treatments that need temporary or chronic reduction of the apoptotic activity, not limitative. The invention further claims the use of Mas G-protein-coupled receptor agonists and antagonists, including the Angiotensin-(1-7) peptide and its analogues, agonists and antagonists, either peptidic or non-peptidic, formulated with pharmaceutically and pharmacologically acceptable excipients or carriers, as modulators of the apoptotic activity. | 12-18-2008 |
| 20080312130 | DRUG DELIVERY VEHICLE FOR CANCER THERAPY, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL PREPARATION USING THE SAME - The invention provides a vehicle that can deliver drugs specifically to the body and a pharmaceutical preparation using the same. Disclosed is a drug delivery vehicle for cancer therapy, comprising a cationized viral envelope vector, as well as a pharmaceutical preparation comprising a drug enclosed in the vehicle. The viral envelope vector is for example HVJ-E derived from a Sendai virus, and cationization can be conducted by binding hyaluronic acid-introduced cationized gelatin or ethylene glycol-introduced cationized gelatin with the viral envelope vector. The drug to be enclosed is a nucleic acid, a vector containing a nucleic acid sequence, a protein based drug or pharmaceutical with a low-molecular compound. | 12-18-2008 |
| 20080312131 | Regeneration of Chromatographic Stationary Phases - Process for regenerating a chromatographic stationary phase | 12-18-2008 |
| 20080312132 | Composition for animal consumption - This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal consumption, particularly compositions that tend to aid in weight loss or reduction in weight gain, and particularly compositions that comprise one or more medium chain fatty acid triglycerides (“MCT”). This invention also is directed generally to methods for using such compositions. This invention is further directed generally to processes for making such compositions. | 12-18-2008 |
| 20080312133 | UNACYLATED GHRELIN AS THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISORDERS - An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism. | 12-18-2008 |
| 20080312134 | Vesicles for active macromolecule delivery - Vesicles for delivery of active macromolecules, such as oligoaminoacids, oligonucleotides, microRNA, siRNA, dsRNA, single stranded oligonucleotides, DNA, peptide nucleic acids, peptides, proteins, and some synthetic organic drugs which are made from amphiphilic segmented copolymers where one segment contains the active macromolecule. In one preferred embodiment, the active macromolecule is contained in the hydrophilic C segment of an amphiphilic ABC segmented copolymer. | 12-18-2008 |
| 20080318834 | Antimicrobial Lactoferrin Compositions for Surfaces, Cavities, and Foodstuff - The present invention relates to a method and composition for decontaminating surfaces, in particular surfaces in the oral cavity or wounded skin, inert surfaces such as from surgical instruments, or food stuffs, such as meat, wherein the method consists of treating the surface with a solution of lactoferrin of acid pH; a solution of lactoferrin and EDTA; a solution of lactoferrin and EDTA of acid pH, or combinations thereof. The solutions may optionally further comprise a polysaccharide, preferably a polysaccharide negatively charged at about neutral pH, such pectin. | 12-25-2008 |
| 20080318835 | Novel Integrin Ligand ITGL-TSP - ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's, disease and tissue remodeling, among others, and diagnostic assays for such conditions. | 12-25-2008 |
| 20080318836 | sCD Fingerprints - The present invention relates to the use of cluster of differentiation (CD) molecules in detecting the presence and progression of one or more disease states in an individual. In particular it relates to the use of profiles of shed CD (sCD) molecules in detecting an assessing the progress of one or more disease states in an individual. Further uses of sCD profiles according to the present invention are also described. | 12-25-2008 |
| 20080318837 | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide - What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome. | 12-25-2008 |
| 20080318838 | PEPTIDES - PTH compounds having PTH-like activity and comprising at least one modification, said modification being either
| 12-25-2008 |
| 20080318839 | Ligand activated transcriptional regulator proteins - Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells. | 12-25-2008 |
| 20090005292 | Novel Peptides that Bind to the Erythropoietin Receptor - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 01-01-2009 |
| 20090011974 | Scavenger Receptor B1 (Cla-1) Targeting for the Treatment of Infection, Sepsis and Inflammation - This invention relates to methods and compositions for the treatment of sepsis, inflammation or infection. In particular, the invention concerns the use of molecule(s) that target SR-BI, which is also referred to as CLA-1 (SR-BI/CLA-1), to treat sepsis, bacterial and viral infections, and inflammatory diseases. SRB I/CLA- | 01-08-2009 |
| 20090011975 | TARGETED BONE MARROW PROTECTION AGENTS - The invention provides a method of inhibiting cell death in a mammal. The method comprises administering to a mammal an effective amount of a composition comprising a cell protection factor covalently linked to a bone targeting agent via a linkage that is cleaved under physiological conditions, whereby the cell protection factor is released from the bone targeting agent in vivo to inhibit cell death. The invention further provides a compound comprising a cell protection factor covalently attached to a bone targeting agent via a linker that is cleaved under physiological conditions. | 01-08-2009 |
| 20090023627 | COMPOSITIONS AND METHODS FOR ALZHEIMER'S DISEASE - The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Aβ) protein or peptide. Anti-Aβ antibodies are selected and sequenced. In certain embodiments, synthetic Aβ binding peptides are designed and prepared, using portions of the anti-Aβ antibody sequences. The antibodies and peptides are of use for treatment of AF or for treatment of individuals at risk of developing AD. Compositions comprising anti-Aβ antibodies or Aβ binding peptides are also disclosed. | 01-22-2009 |
| 20090023628 | Cosmetic Composition and a Process for Preparing This Cosmetic Composition and a Cosmetic Product - The present invention relates to a cosmetic composition comprising: a wetting system that comprises at least glycerin in an amount ranging from 8.0% to 10% by weight, based on the total weight of the composition; an emollient system that comprises at least cetyl lactate and Shea butter; an emulsifying system that comprises at least steareth-2 and steareth-21; an oiliness adsorbing system that comprises at least nylon 12; and a silicone system that comprises at least cyclomethicone and cyclomethicone and dimethicone crosspolymer. This multifunctional cosmetic composition exhibits rapid absorption, properties of differentiated softness, smoothness and intensive and prolonged hydration when applied to the skin. Further, the present invention relates to a process of preparing the referred-to cosmetic composition and to a cosmetic product that comprises said composition. | 01-22-2009 |
| 20090023629 | COMPOSITIONS COMPRISING POLYCATION-COMPLEXED PROTEIN CRYSTALS AND METHODS OF TREATMENT USING THEM - The present invention relates to compositions comprising polycation-complexed protein crystals and hyaluronic acid. Advantageously, the compositions of this invention are stable, long-acting and avoid local reactions at the injection site. Compositions according to this invention include sustained-release human growth hormone compositions. Such compositions are useful for treating a subject having a disorder associated with human growth hormone deficiency or that is ameliorated by human growth hormone therapy. | 01-22-2009 |
| 20090029901 | Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations - A process for producing a plurality of lactose particles comprises subjecting a plurality of lactose particles, to conditions such that at least a portion of smaller lactose particles detach from the plurality of the lactose particles and disperse in the liquid medium; subjecting the liquid medium to conditions sufficient to cause crystallization to occur on the smaller lactose particle surfaces to form larger lactose particles; and subjecting the liquid medium to conditions such that at least a portion of the lactose particles smaller relative to the plurality of larger lactose particles are dissolved in the liquid medium, wherein crystallization occurs on the plurality of larger lactose particles. | 01-29-2009 |
| 20090029902 | PEPTIDES FOR BINDING CALCIUM CARBONATES AND METHODS OF USE - Combinatorially generated peptides are provided that have binding affinity for calcium carbonates. The peptides may be used to deliver benefit agents to various calcium carbonate surfaces. | 01-29-2009 |
| 20090036348 | Use of Novel HNF4a Target Genes and Their Gene Products - Dysfunction of HNF4α may lead to disease and an identification of genes targeted by this factor provides insights into mechanisms of disease. In accordance with the invention thirteen new HNF4α target genes were found (C20orf13, KIAA0774, EPS15R, PLCB1, UGTREL1, RSK4, PAK5, FMR2, NEB, NFYC, KCNQ4, PRPF3, TRPC1). These genes were identified by means of molecular biological and molecular genetic methods. The genes code for various biological functions (metabolism, regulation of cell cycle and signal transduction, differentiation, ion channels, mRNA processing, see table A) and are thus important for the therapy of metabolic disorders, diabetic diseases and tumor growth. In the present invention, additionally eleven new HNF4α target genes are described. It was shown that HNF4α and TPRC1 are regulated in animal models of diabetes. Thus, TPRC1 is a candidate gene for the treatment of diabetic nephropathy. The discovery of the above described target genes of HNF4α and their function comprises an enormous potential for the treatment of metabolic discuses including diabetes and diabetic caused diseases and tumor growth. | 02-05-2009 |
| 20090036349 | Methods and Compositions Related to Targeting Wounds, Regenerating Tissue, and Tumors - Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals. | 02-05-2009 |
| 20090036350 | Method for Stabilisation of a Protein Solution by Addition of Hydroxyl Radical Quenchers and its Sterilisation by Ionising Radiation - A method of sterilising a protein in an aqueous environment, comprises exposing to ionising radiation an aqueous composition comprising the protein with a protective compound or combination of protective compounds having the following characteristics: (i) a rate of reaction with hydroxyl radicals greater than 5×10 | 02-05-2009 |
| 20090036351 | USE OF A PROTEIN HYDROLYSATE FOR ENHANCING ACTIVITY OF GLUCAGON-LIKE PEPTIDE-1 - A protein hydrolysate having a degree of hydrolysis between 1 and 40% and containing between 1 and 70 wt. % of peptides having a molecular weight of less than 500 Da and less than 55 wt. % of peptides or proteins having a molecular weight of more than 5000 Da, on the basis of the total proteinaceous material of the composition, is effective in stimulating secretion of glucagon-like peptide-1 (GLP-1). In addition, the hydrolysate may have DPP-IV inhibiting activity. The hydrolysate is suitable for the manufacture of a medicament, or food product for prophylaxis and/or treatment of a GLP-1 mediated condition, in particular obesity, type 2 diabetes mellitus and an immunological disorder. | 02-05-2009 |
| 20090036352 | DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES COMPRISING RAPAMYCIN AND DERIVATIVES THEREOF - Provided are drug delivery systems for the prevention and treatment of proliferative diseases, particularly vascular diseases, comprising rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents. | 02-05-2009 |
| 20090042768 | Purine derivatives and their use for treatment of autoimmune diseases - Compounds useful in the treatment of autoimmune disease are described by the following general formula: | 02-12-2009 |
| 20090042769 | MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY - The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake. | 02-12-2009 |
| 20090042770 | Branched Chain Amino Acid Chelate - Compositions are disclosed comprising mineral/branched-chain amino acid chelates such as, for example, calcium leucinate, for increasing absorption of the branched-amino acid in a human or animal subject. Methods are also provided for using the compositions to increase branched-chain amino acid absorption to increase or maintain muscle mass in athletes or in individuals having diseases such as ALS, muscular dystrophy, sarcopenia associated with aging, or muscle atrophy associated with spinal cord injury, as well as to decrease mental fatigue. | 02-12-2009 |
| 20090042771 | DIETARY LIPIDS FOR IMPROVING SKIN AND COAT OF PETS - A source of dietary lipids containing anti-microbial fatty acids is added to a food composition intended for improving or maintaining the skin health and/or coat quality in a pet by preventing or regulating the growth of skin pathogens and of microflora responsible for the generation of body surface and coat odors. | 02-12-2009 |
| 20090048145 | In situ hardening paste, its manufacturing and use - An in-situ-hardening paste, containing an organic or inorganic filling material, a biodegradable polymer and a water soluble polymeric plasticizer was developed as a delivery system for an active agent with scaffold properties in the field of tissue regeneration. The hardened paste is sufficient mechanical stable to can be used as bone and cartilage replacement matrix. All components are full biocompatible, preferably bioresorbable and certified for parenteral application. The sustained release of peptides and proteins can be modulated by the composition and process design. The invention encompasses a pharmaceutical composition comprising the paste of the invention and relates to the use of said paste for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. | 02-19-2009 |
| 20090048146 | USE OF AGENTS THAT UPREGULATE CRYSTALLIN EXPRESSION IN THE RETINA AND OPTIC NERVE HEAD - The present invention relates to methods to treat and/or prevent optic nerve damage in a subject by administering a composition comprising a crystallin agonist. | 02-19-2009 |
| 20090048147 | NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES - The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: | 02-19-2009 |
| 20090048148 | COMPOSITIONS AND METHODS FOR THERAPEUTIC USE - A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent. | 02-19-2009 |
| 20090048149 | Antagonists of the bradykinin B1 receptor - The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor. | 02-19-2009 |
| 20090048150 | Materials and Methods for the Detection of Nitrated Fibrinogen - Compositions are disclosed for detecting a patient's risk for coronary artery disease. The compositions can determine the presence of nitrated fibrinogen which is linked with coronary artery disease. Kits for the detection of coronary artery disease are also provided. | 02-19-2009 |
| 20090048151 | PEG-Poly(Ortho Ester) Graft Copolymers and Pharmaceutical Compositions - This invention relates to graft copolymer delivery vehicles comprising a polyethyleneglycol-poly(ortho ester), and to controlled release pharmaceutical compositions comprising the delivery vehicle and an active agent. The graft copolymer delivery vehicles may be thermogels graft copolymers. The pharmaceutical compositions may be in the form of a topical, syringable, or injectable formulation for local controlled delivery of the active agent. | 02-19-2009 |
| 20090054300 | Compositions and Methods for the Treatment of Systemic Lupus Erythematosis - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases | 02-26-2009 |
| 20090054301 | HYPOALLERGENIC COMPOSITION - This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal (including pet) consumption, and particularly hypoallergenic compositions, and more particularly semi-solid hypoallergenic compositions and hypoallergenic compositions that comprise a hydrolysate. This invention also is directed generally to methods for using such compositions. This invention is further directed generally to processes for making such compositions. | 02-26-2009 |
| 20090062178 | METHODS OF USE OF GAMMA INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN - The disclosure herein relates to modified γPKC inhibitory peptides, methods of generating such peptides, and method for using γPKC inhibitory peptides for the treatment of pain. | 03-05-2009 |
| 20090062179 | Diagnosing and Treating Hormone Resistant Cancers - Provided herein are methods and compositions related to diagnosing and treating hormone resistant cancers. | 03-05-2009 |
| 20090069213 | Compositions for Improving the Health and Appearance of Skin - Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin. | 03-12-2009 |
| 20090069214 | Modulator of Metabolism Processes and Method of Its Receiving - A modulator of metabolic processes and method of manufacturing same is provided. The invention may have applicability in at least the fields of medicine, veterinary medicine, medical industry, and agriculture. The essence of invention is a chemically modified biopolymer with a polypeptide chain as an exogenous modulator of metabolic and energy exchange processes between a cell and environment, characterized in that it comprises chlorine atoms covalent-bonded with nitrogen atoms of polypeptide chain to the amount of 0.5 to 40% of the total mass of modified biopolymer, whereas the polypeptide chain includes methionine sulfoxide, cysteinic, α-aminomalonic and α-aminoacetoacetic acids to the amount of 1-20 acid residues per 1 mole of final product. The proposed modulator possesses large resource of free energy due to high degree of oxidation, thus ensuring catalytic activity when interacting with clue enzymes and return of particular organs and systems to normal physiological condition. | 03-12-2009 |
| 20090075860 | TRANSDERMAL ABSORPTION ENHANCER - An object of the present invention is to provide a transdermal absorption enhancer by which various active ingredients are transdermally absorbed. In accordance with a transdermal absorption enhancer of the present invention which effective ingredient is lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, transdermal absorption of a macromolecular substance and a water-soluble substance was able to be improved. | 03-19-2009 |
| 20090075861 | SYSTEMS AND METHODS OF REMOVING AND MANAGING HEAVY METALS - Systems and methods remove and manage heavy metals. In one implementation, an exemplary method can be applied to food processing and food consumption to remove heavy metals such as mercury, lead, uranium and cadmium before absorption by a living organism. The exemplary method exposes the food to a heavy-metal binding ligand, such as a concentrated protein or phytic acid, to form a heavy-metal chelate, and then allows the chelate to separate from the food. In another implementation, an exemplary probe possesses innovative molecular layers on its surface to detect and quantify heavy metals by attracting and binding traces of the heavy metals on a ligand layer. | 03-19-2009 |
| 20090075862 | METHOD FOR PROVIDING GLUTAMINE - A method of providing glutamine to a patient. A nutritional composition which includes whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source is enterally administered to the patient. The whey protein may be a hydrolyzed whey protein. The patient may be a stressed patient, pre-term baby, or athlete. | 03-19-2009 |
| 20090082249 | NUTRITIONAL SUPPLEMENT FOR A CATEGORY OF HIV PATIENTS - The present invention relates to a nutritional product for HIV patients that are not on Highly Active Antiretroviral Therapy. More specifically the invention relates to a nutritional composition comprising oligosaccharides. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients. | 03-26-2009 |
| 20090082250 | Control of gene expression using a complex of an oligonucleotide and a regulatory peptide - A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase. | 03-26-2009 |
| 20090082251 | Mitochondrial DNA variants associated with metabolic syndrome - Provided are methods of identifying Metabolic Syndrome phenotypes for an organism or a biological sample derived therefrom which methods are based on detecting a polymorphism, haplotype, haplotype group, or haplotype subgroup in the mitochondrial genome of the organism and correlating the polymorphism or haplotype to a Metabolic Syndrome phenotype. Also provided are systems or kits for the detection of such polymorphisms or haplotypes and the correlation of the polymorphisms or haplotypes to a Metabolic Syndrome phenotype. Provided are methods of identifying a modulator of a Metabolic Syndrome phenotype and kits for the treatment of a Metabolic Syndrome phenotype. | 03-26-2009 |
| 20090082252 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use - The invention relates generally to peptides comprising one or more non-natural amino acids residues and their use in cosmetic and personal care compositions. | 03-26-2009 |
| 20090082253 | Antibacterial agent based on fatty acid esters of hydroxy carboxylic acid acids - The present invention relates to an antibacterial composition based on a combination of fatty acid ester of fatty acid and hydroxy carboxylic acid with an antibacterial agent selected from polylysine, protamine, their salts and mixtures hereof. The hydroxy carboxylic acid may be present as acid in its free form, in its salt form and/or in its ester form. | 03-26-2009 |
| 20090082254 | Coupling of Polypeptides at the C-Terminus - The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications. | 03-26-2009 |
| 20090088364 | Pharmaceutical composition useful for the treatment of invasive pulmonary aspergillosis - The present invention provides a pharmaceutical composition comprising purified human mannan-binding lectin (MBL) optionally along with carriers administered at a unit dose in the range of 1.0 μg-5.0 μg/20 kg body weight. Further, it also deals with a method and use thereof for the treatment of invasive pulmonary aspergillosis using said composition. | 04-02-2009 |
| 20090088365 | Biosynthetic Polypeptide Fusion Inhibitors - Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided. | 04-02-2009 |
| 20090088366 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E | 04-02-2009 |
| 20090093395 | METHOD FOR DETERMINING PREDISPOSITION TO PULMONARY INFECTION - Provided herein are methods and materials for diagnosing a subject's predisposition for pulmonary infection in a CF subject by detecting a pulmonary infection genetic marker. Pulmonary infection markers have been identified in the IL-1 gene cluster and may be useful in predicting CF disease progression and assessing a CF subject's response to therapy. | 04-09-2009 |
| 20090093396 | DIAGNOSTICS AND THERAPEUTICS FOR RESTENOSIS - Methods and kits for determining whether a subject has or is predisposed to developing restenosis are provided. | 04-09-2009 |
| 20090099060 | Modulation of line-1 reverse transcriptase - A reverse transcriptase encoded by L-1 (LINE-1) has been identified as a target molecule for treating or preventing cancers induced or mediated by this molecule. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptase in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing L1RT are also disclosed. | 04-16-2009 |
| 20090099061 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS - A method is described for synthesizing and administering carotenoid compounds with improved antioxidant characteristics. In some embodiments, extension or improvement of conjugation may be employed in structural modification of carotenoids. In other embodiments, reduction of ring/chain steric hindrance may improve the lambda max, and hence, the overall antioxidant capability, of particular compounds. In other embodiments, introduction and/or increase in synthetic handles for conjugation may improve the stoichiometric ratios of conjugating moieties to the polyene backbone. The methods may be used to improve natural and/or synthetic compounds for medicinal application in the treatment of disease. | 04-16-2009 |
| 20090099062 | Pyrvinium For The Treatment of Cancer - The present invention concerns a pyrvinium compound or an analog thereof for the treatment of cancers. This compound inhibits Wnt activity in the cells of cancers such as adrenocortical, hepatocellular, hepatoblastoma, malignant melanoma, ovarian, Wilm's tumor, Barrett's esophageal, glioma, bladder, breast, gastric, head & neck, lung cell, mesothelioma, and cervical cancers. The present invention also provides a method for assaying for compounds that alter Wnt pathway activity. Also provided are methods for treating Wnt-related non-cancer disease states. | 04-16-2009 |
| 20090099063 | SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4 | 04-16-2009 |
| 20090105115 | POLYAMIDES FOR NUCLEIC ACID DELIVERY - The present invention provides a new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications. The present invention also provides a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response. Complexes according to the invention or portions thereof, can comprise a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells. In some embodiments, cellular delivery molecules for use in the present invention may comprise one or more polymers of the present invention, e.g., polyamides, dendritic macromolecules and carbohydrate-containing degradable polyesters. | 04-23-2009 |
| 20090105116 | Polypeptide Ligands Containing Linkers - There is provided herein a multivalent binding molecule and uses thereof. The molecule is useful in binding a target under certain conditions and releasing it under other conditions. The molecule has the general formula (1) of BM1-L-(BM2) | 04-23-2009 |
| 20090105117 | STEM CELLS AND LIM MINERALIZATION PROTEINS - Methods of changing a phenotype of a cell are provided. The methods comprise increasing an amount of an amino acid sequence which is at least 70% identical to an amino acid sequence encoding an LMP protein or a fragment thereof in a cell. The cells may be contacted by either a composition comprising a nucleic acid sequence encoding the amino acid sequence which is at least 70% identical to the amino acid sequence encoding an LMP or its fragment or by a composition comprising acid sequence which is at least 70% identical to the amino acid sequence encoding an LMP or its fragment or any combination thereof. The cells may be contacted either in vivo or ex-vivo. | 04-23-2009 |
| 20090105118 | Preparation and applications of novel complexes made by gamma-polyglutamic acid and cisplatin - A series of complexes made by γ-polyglutamic acid (γ-PGA) and cisplatin, their preparation and applications in biomedical field, specifically in cancer treatment. The complexes may be made by binding free cisplatin on small molecule γ-PGA through the reaction between carboxylic group of γ-PGA and Cl of cisplatin. The complexes show effective anticancer effect and are easy and cost effective to prepare. | 04-23-2009 |
| 20090105119 | ASPARAGINE-10-SUBSTITUTED NONADEPSIPEPTIDES - The invention relates to nonadepsipeptides and methods for their preparation, as well as to their use for manufacturing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases. | 04-23-2009 |
| 20090105120 | METHOD FOR PREPARING TRYPTOPHAN RICH PEPTIDES - Described is a method for selectively isolating tryptophan containing peptides from an aqueous peptide mixture, including the steps of controlling the pH of the aqueous peptide mixture to 4.0-6.0, forming a precipitate of tryptophan containing peptides, and isolating the precipitated peptides. | 04-23-2009 |
| 20090111730 | Polypeptide protracting tags - Method for increasing (protracting) half-life of LGP analogs in plasma and novel derivatives of such peptides based on covalently linking them to a tetrazole moiety which acts as a carboxylic acid bioisostere. | 04-30-2009 |
| 20090111731 | NOVEL TOPICAL APPLICATION AGENTS AGAINST MIMIC AND AGE-RELATED WRINKLES - The compounds of formula (I) | 04-30-2009 |
| 20090111732 | Gelling Hydrophobic Injectable Polymer Compositions - Biodegradable carriers synthesized from ricinoleic acid oligoesters and aliphatic molecules having at least one carboxylic acid and at least one hydroxy or carboxylic acid group that are liquids or pastes at temperatures below 37° C. and methods of making and using thereof are described herein. The polymers described herein significantly increase their viscosity upon immersion in aqueous medium. These polymers can be used as hydrophobic biomedical sealants, temporary barriers to prevent adhesions, such as organ to organ adhesion, cell supports, carriers for drug delivery, and coatings on implantable medical devices, such as stents. The polymers made from ricinoleic acid oligoesters are less viscous and easier to inject compared to polymers of similar composition and molecular weight prepared from ricinoleic acid monomers, possess a higher molecular weight, retain an incorporated drug for longer periods, and degrade into soft degradation products at a slower rate compared with polymers synthesized from ricinoleic acid monomers. Pharmaceutically active agents can be incorporated into the liquid or pastes without the use of organic solvents. | 04-30-2009 |
| 20090111733 | PAR-4 RELATED METHODS AND COMPOSITIONS - Provided herein are methods and compositions for treating or preventing mood disorders and certain other mental disorders. Methods may comprise increasing PAR-4 levels or activity and/or the interaction between PAR-4 and the dopamine (D2) receptor | 04-30-2009 |
| 20090111734 | COMPOSITIONS AND METHODS FOR PROMOTING HEMOSTASIS AND OTHER PHYSIOLOGICAL ACTIVITIES - Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaiminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described. | 04-30-2009 |
| 20090118158 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY - Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation. | 05-07-2009 |
| 20090124534 | Trehalose Click Polymers for Delivery of Biologically Active Molecules - Novel trehalose click polymers have in vitro and in vivo application in the cellular delivery of biologically active molecules, including nucleic acids and polypeptides. The trehalose click polymers of the present invention provide increased stability in serum as compared with other non-viral vectors, and are particularly useful in protecting nucleic acids against degradation. | 05-14-2009 |
| 20090124535 | VISCOUS TERPOLYMERS AS DRUG DELIVERY PLATFORM - Disclosed are terpolymer compositions of lactide, glycolide, and caprolactone and methods of making such polymers with an initiator. Methods of using the terpolymers as a drug delivery platform are also disclosed. | 05-14-2009 |
| 20090124536 | CALCIUM PHOSPHATE/SULFATE-BASED BONE IMPLANT COMPOSITION - A bone implant composition, the composition comprising calcium sulphate and slowly soluble source of calcium, orthophosphate and hydroxyl ions. The composition may be provided in powder or granulated form. | 05-14-2009 |
| 20090131302 | Transient receptor potential vanilloid 1 and uses thereof - The present invention describes methods of retarding the development of visceral and somatic hypersensitivities in an individual. Further, the present invention describes a potentially important role for the transient receptor potential vanilloid 1 (TRPV1) in initiation and maintenance of the chronic visceral hypersensitivity and its role in development of irritable bowel syndrome. | 05-21-2009 |
| 20090137451 | Methods for Assessing Suitability of Cancer Patients for Treatment with Histone Deacetylase Inhibitors - This invention is in the field of cancer therapy and provides the use of E2F1 activity for assessing suitability of a cancer patient for treatment with histone deacetylase inhibitors (HDACIs). | 05-28-2009 |
| 20090137452 | Antagonists of the bradykinin B1 receptor - The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor. | 05-28-2009 |
| 20090137453 | COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE TO INHIBIT MIGRATION OF LANGERHANS CELLS, AND USES THEREOF - The invention concerns a composition containing at least an oxazolin, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an alkanolamide, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such composition on the skin and/or mucosa. | 05-28-2009 |
| 20090143275 | ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 06-04-2009 |
| 20090143276 | Trimeric IL-1Ra - Interleuekin-1 receptor antagonists (IL-1Ra) including fusion proteins having a trimerizing domain and an IL-1Ra polypeptide sequence. The fusion proteins are part of trimeric complexes that are used in pharmaceutical compositions for treating diseases mediated by IL-1. Effective treatment of inflammatory diseases, such as rheumatoid arthritis and diabetes, are described. | 06-04-2009 |
| 20090143277 | NUTRITIONAL COMPOSITION FOR CONTROLLING BLOOD SUGAR LEVEL - A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and/or trehalulose in the carbohydrate energy percentage is 60 to 100%. | 06-04-2009 |
| 20090143278 | PROCESS FOR PREPARING BIOACTIVE PROTEIN-ENRICHED WHEY PRODUCTS - The present invention involves the discovery that various liquid (whey) streams drained or expelled from cheese curd after salt addition in the preparation of cheese contain enriched levels of bioactive proteins such as lactoferrin, lactoperoxidase, immunoglobulins, and growth factors. According to the invention, these proteins may be further enriched through manipulation of the cheese salting process as described herein. The methods of the invention may be used to produce various whey products with enriched levels of all the above bioactive proteins present and, through manipulation of salting conditions, to enrich these proteins selectively. | 06-04-2009 |
| 20090149371 | TREATMENT OF NEUROLOGICAL DEFICITS IN THE STRIATUM OR SUBSTANTA NIGRA PARS COMPACTA - The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments. | 06-11-2009 |
| 20090156457 | METHODS AND MEANS FOR SCREENING FOR RHOMBOID ACTIVITY - This invention relates to methods of screening for rhomboid modulating compounds using a substrate polypeptide has a core domain comprising a rhomboid cleavable TMD sequence linked to an upstream tag sequence. The core domain sequence is not susceptible to cleavage by non-rhomboid proteases so products of rhomboid dependent proteolysis products may be detected by determining the presence of the tag sequence. Rhomboid modulating compounds identified by the present methods may be useful in a range of therapeutic applications. | 06-18-2009 |
| 20090156458 | ASSAY FOR THE DETECTION OF FACTORS THAT MODULATE THE EXPRESSION OF INAGP - A reporter construct contains mammalian INGAP 5′-regulatory region or a fragment thereof, a minimal promoter element from mammalian INGAP or a heterologous promoter, and a reporter gene. The reporter construct can be used to screen for agents which alone or in combination up-regulate or down-regulate reporter gene expression. Alternatively, the reporter construct can be used to screen for agents that bind to the hamster INGAP 5′-regulatory region or a fragment thereof. | 06-18-2009 |
| 20090156459 | Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same - The present invention relates to a biocompatible cationic-core carrier composition that has sustained release capability and includes a polymeric backbone, protective chains, poly-cationic moieties and optionally an anionic load molecule. | 06-18-2009 |
| 20090156460 | CATIONIC BETAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES - Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent delivery systems. | 06-18-2009 |
| 20090156461 | Novel Bacillus Thuringiensis Gene with Lepidopteran Activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 06-18-2009 |
| 20090156462 | USE OF FIBROUS TISSUE INDUCING PROTEINS FOR HERNIA REPAIR - The present disclosure relates to hernia repair and methods for stimulating growth of fascia tissue employing compositions comprising fibrous tissue inducing proteins. | 06-18-2009 |
| 20090170748 | Plasmid mediated supplementation for treating chronically ill subjects - The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and methods are useful for treating anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the animal tissue specific constitutive expression is achieved. | 07-02-2009 |
| 20090170749 | Novel Compounds Which Interact With PEA-15 - The present invention relates to novel pseudopeptide compounds of defined formula, capable of interacting with the PEA-15 protein and to the use thereof in screening methods and to a method of diagnosing pathological conditions which may involve PEA-15. | 07-02-2009 |
| 20090186801 | Methods of Inhibiting Tumor Cell Aggressiveness Using The Microenvironment of Human Embryonic Stem Cells - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 07-23-2009 |
| 20090186802 | Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell - The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed. | 07-23-2009 |
| 20090186803 | USE OF NUTRITIONAL COMPOSITIONS WITH PHOSPHOLIPID, SPHINGOLIPID AND CHOLESTEROL. - A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided. | 07-23-2009 |
| 20090186804 | ANTICOAGULANT AND COMPOSITION FOR PREVENTING THROMBUS CONTAINING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood vessels, shows an excellent sustained-release effect and is harmless to the human body. Thus, it is useful as a high-value-added anticoagulant and a food or beverage composition for preventing thrombus formation. | 07-23-2009 |
| 20090186805 | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance - Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as reduced skin sagging, increased skin thickness, reduced wrinkles, increased skin thickness and collagen content, increased skin tone and elasticity, increased skin hydration, and improved skin texture and color. | 07-23-2009 |
| 20090186806 | Truncated Activin Type II Receptor and Methods of Use - The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject. The invention also provides a method of modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects myostatin signal transduction to the organism. | 07-23-2009 |
| 20090192071 | USE OF PHOTODYNAMIC THERAPY TO ENHANCE TREATMENT WITH IMMUNO-MODULATING AGENTS - Methods of enhancing the efficacy and safety of treatment with immuno-modulating agents are provided. The inventive methods combine treatment with immuno-modulating agents with photodynamic therapy (PDT). PDT can be administered before, during or after administration of the immuno-modulating agent. Combination therapy achieves at least the same efficacy as immuno-modulatory therapy in less time, with less immuno-modulating agent and fewer side-effects. | 07-30-2009 |
| 20090192072 | Insulin and IGF-1 Receptor Agonists and Antagonists - Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics. | 07-30-2009 |
| 20090203572 | Method for in Vitro Molecular Evolution of Protein Function - The invention provides a method for generating a polynucleotide sequence or population of sequences from parent polynucleotide sequences, the method comprising the steps of (a) providing a first population of polynucleotide molecules and a second population of polynucleotide molecules, the first and second populations together constituting plus and minus strands of parent polynucleotide sequences, (b) digesting the first and second populations of polynucleotide molecules with a nuclease to generate polynucleotide fragments, (c) contacting said polynucleotide fragments generated from the plus strands with fragments generated from the minus strands and (d) amplifying the fragments that anneal to each other to generate at least one polynucleotide sequence encoding one or more protein motifs having an altered amino acid sequence as compared to those encoded by the parent polynucleotides, wherein the degree of sequence variability in a selected region of the at least one polynucleotide molecule produced in step (d) is controlled by the addition of one or more oligonucleotides of predetermined variability, which oligonucleotides anneal to a sequence that lies between, but excludes, the 3′ or 5′ terminal nucleotide of the parent polynucleotide molecule. The invention also provides polynucleotides obtained by the method of the invention and polypeptides encoded by the same. | 08-13-2009 |
| 20090203573 | USE OF DIETARY FIBRES AGAINST MUSCLE WASTING - A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units. | 08-13-2009 |
| 20090203574 | Method for Modulating Hair Growth - The present invention relates to the use of Lhx2 as a target for modulating the hair growth. Screening assays for identifying agents which increase or decrease the expression or activity of Lhx2 are provided. | 08-13-2009 |
| 20090203575 | TARGETED THERAPEUTIC PROTEINS - Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided. | 08-13-2009 |
| 20090209450 | MicroRNA Fingerprints During Human Megakaryocytopoiesis - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer and myeloproliferative disorders. The invention also provides methods of identifying anti-cancer agents. | 08-20-2009 |
| 20090209451 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES - The present invention relates to heteroarylaminopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders. | 08-20-2009 |
| 20090215665 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject. | 08-27-2009 |
| 20090215666 | VIVIT POLYPEPTIDES, THERAPEUTIC AGENT COMPRISING THE SAME, AND METHOD OF SCREENING FOR ANTI-CANCER AGENT - The present invention provides polypeptides useful for treating and preventing cancer. The present invention also provides therapeutic agents or methods for treating cancer using the polypeptides. The polypeptides of the present invention are composed of an amino acid sequence which comprises VIVIT and is preferably a polypeptide in which the motif sequence PxIxIT at positions 37 to 41 of the amino acid sequence of the C1958 protein (SEQ ID NO: 2) is replaced with PVIVIT. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. The present invention provides methods and kits for identifying inhibitors of the interaction between C1958 and PPP3CA which find utility in the treatment and prevention of cancer. Also disclosed herein are compositions for treating or preventing cancer identified by the screening method of the present invention and methods of using same in the treatment and prevention of cancer. | 08-27-2009 |
| 20090215667 | Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants - The present invention relates to plant proteins produced by a plant's epidermal layer that contribute to the innate pest/disease resistance of the plant (“phylloplanins”), compositions comprising the phylloplanins and methods of using them. In particular the methods relate to inhibiting or preventing microbial, e.g., fungal or bacterial, growth on a subject, organism or surface by administering a phylloplanin. The invention also relates to transformed host cells that produce phylloplanins, and to transgenic plants producing phylloplanins conferring increased resistance to microbial infections/growth. | 08-27-2009 |
| 20090215668 | Methods of making and uses of compositions that modulate intronic region-encoded protein function - This invention relates to compositions and methods for modulating cellular activity of non-human organisms, and in particular fungi, and methods of identifying and using antifungal agents with improved specificity. More particularly, the technology described herein relates to the identification and use of compounds that target intron-encoded proteins, such as maturases. | 08-27-2009 |
| 20090221468 | Autonomously Replicating KSHV CIS-Acting Elements - This invention provides methods of reducing a replication of a gammaherpesvirus genome, treating a KSHV infection, and treating or reducing an incidence of a KSHV-associated disease, comprising contacting a subject with a composition that inhibits initiation of DNA replication from a region of a genome of a gammaherpesvirus. The invention also provides isolated DNA molecules capable of episomal replication in a eukaryotic cell, and methods of delivering a recombinant protein or therapeutic RNA molecule, comprising same. | 09-03-2009 |
| 20090221469 | USE OF SOY KEFIR POWDER FOR REDUCING PAIN, BLOOD PRESSURE AND INFLAMMATION - The present invention relates to a soy kefir powder produced by the fermentation of soy milk with Kefir grains of the Moscow strain under suitable fermentation conditions. The soy kefir powder of the invention has at least one of the following biological activities: pain relief, blood pressure reduction and inflammation reduction. The present invention also relates to the method of production of the soy kefir powder of the invention. It also relates to the use of the soy kefir powder of the invention for pain relief, blood pressure reduction and inflammation reduction. The invention also relates to methods for pain relief, blood pressure reduction and inflammation reduction by using the soy kefir powder of the invention. | 09-03-2009 |
| 20090239782 | High-molecular weight conjugate of resorcinol derivatives - Provided is a high-molecular weight conjugate of resorcinol derivatives which is excellent in water solubility and stability and has high antitumor activity even when used in a smaller total drug amount than the resorcinol derivatives. The high-molecular weight conjugate of resorcinol derivatives comprises a structure in which a carboxyl group of polymer moiety having a carboxyl group in the side chain and polyethylene glycol moiety is linked to a hydroxyl group of resorcinol derivatives via an ester bond. | 09-24-2009 |
| 20090239783 | SYNERGISTIC EFFECTS OF COMBINED ADMINISTRATION OF MIRTAZAPINE AND A STIMULANT COMPOUND - The invention discloses combination therapies and formulations of a stimulant (e.g., amphetamine) and mirtazapine and their methods of use. | 09-24-2009 |
| 20090253613 | Solid-Fluid Composition - A nanostructure comprising a core material of a nanometric size surrounded by an envelope of ordered fluid molecules is disclosed. The core material and the envelope of ordered fluid molecules are in a steady physical state. Also disclosed, a liquid composition comprising liquid and the nanostructure. | 10-08-2009 |
| 20090258814 | Method for treating a synucleinopathy - The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor. | 10-15-2009 |
| 20090258815 | ANTIVIRAL PEPTIDE AND ANTIVIRAL AGENT - Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear localization sequence (NLS)) or an amino acid sequence having a partial modification in the NLS and also having at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as a nuclear export sequence (NES)) or an amino acid sequence having a partial modification in the NES. | 10-15-2009 |
| 20090258816 | USE OF GPCR AGONISTS TO DELAY PROGRESSION OF DIABETES - The present invention is directed to the use of G-protein coupled receptor agonists for the treatment of beta-cell degeneration. | 10-15-2009 |
| 20090270308 | Controlled release implantable dispensing device and method - A dispensing device having a polymer which is combined with a therapeutic agent in the form of a microparticle or nanoparticle which is “hyper-compressed” to form a controlled release dispensing device and methods of locally administering a therapeutic agent using said microparticles. | 10-29-2009 |
| 20090275495 | METHODS AND COMPOSITIONS RELATING TO ALZHEIMER'S DISEASE - Methods and compositions relating to Alzheimer's disease are provided, including proteins that are differentially expressed in Alzheimer's disease as compared to the normal state. Further provided are methods, particularly experimental paradigms, for the identification of differential expressed proteins that are potential molecular targets for compounds to treat or prevent Alzheimer's disease. Also provided are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease. | 11-05-2009 |
| 20090275496 | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods - The instant invention provides methods for the detection and quantitation of complex peptide mixtures in tissue samples and functional readouts of the results of administration of such complex peptide mixtures. The instant invention further provides methods for administering complex peptide mixtures to a subject in need thereof, the dosage regimen and quantity determined based on the above mentioned method for detection and quantitation. | 11-05-2009 |
| 20090281019 | COMPOSITIONS AND METHODS FOR TREATING ATRIAL FIBRILLATION - The present invention provides compositions and methods for treating heart conditions. In particular, the present invention provides compositions and methods that block G protein coupled receptor mediated signaling for treating atrial fibrillation. | 11-12-2009 |
| 20090286713 | Collagen Receptor I-Domain Binding Modulators - The present invention relates to a refined and detailed molecular model of the α2⊕1 integrin I-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially α2β1 integrin modulators. The present invention further relates to novel α2β1 I-domain modulators, which are of therapeutic potential. The present invention further relates to specific families of small molecule modulators interacting with collagen receptors, tetracyclic polyketides and sulfonamides. The present invention further relates to the use of such modulators for the manufacture of medicaments for thrombosis, inflammation and/or cancer | 11-19-2009 |
| 20090286714 | Novel molecules of the card-related protein family and uses thereof - Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-9, CARD-10, or CARD-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 11-19-2009 |
| 20090291877 | TREATMENTS USING CITRULLINE - The invention provides a method and formulation for the treatment or maintenance of conditions that would be benefited from increasing or maintaining Arginine levels in the blood, and having improved taste characteristics over current Arginine supplementations. Further, this maintenance of Arginine levels in the blood will be beneficial in acute and chronic diseases with an impaired arginine to citrulline production rate. Further the invention provides a method for treating at least one of satiety and dyspepsia in an individual. In one embodiment, the method includes administering to an individual an effective amount of L-citrulline. | 11-26-2009 |
| 20090291878 | MODULATORS OF PROTEIN PHOSPHATASE 2A HOLOENYME - Atomic coordinates for human serine/threonine protein phosphotase 2A (PP2A) holoenzyme, as well as methods for using these atomic coordinates to prepare inhibitors of PP2A and inhibitors prepared using such methods are provided herein. A biochemical analysis of the interactions of PP2A holoenzyme is also provided. Compositions including mimetics and small molecules of the invention and, optionally, secondary agents may be used to treat disorders in which PP2A activity plays a contributing role. | 11-26-2009 |
| 20090298740 | NOVEL NUCLEOTIDE SEQUENCES - The present invention relates to the field of cancer therapy. More specifically, the invention relates to use of certain nucleotide sequences for the treatment of cancer. | 12-03-2009 |
| 20090298741 | Trophic Factor Combinations for Nervous System Treatment - The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor and a neuropeptide. The present invention also relates a method of treating an injury to a nervous system of an animal that includes the steps of identifying the injury to the nervous system and applying to the injury an effective amount of at least one of antimicrobial peptide and a substance having an antimicrobial peptide effect. The method can also include applying an effective amount of one or more trophic factors selected from the group consisting of a growth factor, a neurotrophin, and a neuropeptide to the injury. | 12-03-2009 |
| 20090298742 | PROCESS FOR MANUFACTURING LACTOSE - A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions sufficient to cause crystallization to occur on the nanosized lactose particles such that a plurality of lactose particles are formed therefrom having a median diameter ranging from about 4 μm to about 20 μm. | 12-03-2009 |
| 20090298743 | HYDROPHOBIC COMPOSITIONS CONTAINING RECONSTITUTION ENHANCER - Disclosed are compositions comprising a hydrophobic active agent, a polymer and a reconstitution enhancing agent. Reconstitution of the lyophilized form of the compositions takes less time than in the absence of the enhancing agent. | 12-03-2009 |
| 20090305944 | Methods for Providing Palliative Care with AVR 118 - The invention relates to methods for providing palliative care. Specifically, methods for treating patients having an end-stage disease, such as cancer, comprising administering an effective amount of AVR118 are disclosed. Pharmaceutical compositions and kits comprising AVR118, an additional medicament, and pharmaceutically acceptable carriers are also disclosed. The disclosed methods are useful for treating cachexia and/or improving the quality of life in patients near the end of life. | 12-10-2009 |
| 20090305945 | NOVEL NUTRACEUTICAL COMPOSITIONS - The present invention describes a composition which comprises a protein hydrolysate or a protein hydrolysate and one amino acid hydrolysate for the long term treatment or prevention of type 2 diabetes or pre-diabetes or metabolic syndrome or obesity. | 12-10-2009 |
| 20090305946 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease. | 12-10-2009 |
| 20090312232 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 12-17-2009 |
| 20090312233 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 12-17-2009 |
| 20090312234 | Antifungal Paints and Coatings - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 12-17-2009 |
| 20090318329 | METHODS FOR ASSESSING SUITABILITY OF CANCER PATIENTS FOR TREATMENT WITH HISTONE DEACETYLASE INHIBITORS - This invention is in the field of cancer therapy and provides the use of E2F1 activity for assessing suitability of a cancer patient for treatment with histone deacetylase inhibitors (HDACIs). | 12-24-2009 |
| 20090318330 | COMBINATION OF AMINO ACID SOLUTION AND A GELATIN DERIVATIVE FOR INHIBITING RENAL UP-TAKE - The invention relates to a combination of a solution of a gelatin derivative and at least one amino acid, if desired in the form of a pharmaceutically acceptable salt or carboxylic acid derivative, for inhibiting renal uptake of substances, that are potentially damaging for the kidneys, in a living being. | 12-24-2009 |
| 20090325856 | Composition Designed For The Treatment Of Multiple Sclerosis - A composition for controlling the progression of multiple sclerosis includes at least:
| 12-31-2009 |
| 20090325858 | Reduction of Zinc-Induced Neurotoxic Injury By Blockade of Nitric Oxide Synthesis - The present invention provides methods of inhibiting release of zinc from neurons and of preventing zinc-mediated brain injury. Also provided are methods of improving cerebral blood flow while preventing zinc-mediated brain injury. Inhibitors of or activators of nitric oxide synthases modulate nitric oxide synthesis to reduce nitric oxide-induced release of neurotoxic amounts of zinc, thereby reducing zinc-mediated neuronal injury after brain trauma. | 12-31-2009 |
| 20090325859 | CITRIC ACID POLYMERS - The present invention provides polymers (e.g., elastomeric citric acid polymers) and methods of making and using these polymers (e.g., as a biologically active molecule delivery platform). In certain embodiments, the polymer has adsorbed biologically active molecules. In particular embodiments, the polymer comprises pores that are between about 7 and 15 nanometers in diameter. In other embodiments, the polymer comprises poly(1,8 octanediol-co-ctric acid). In certain embodiments, the polymers are made by employing polyethylene glycol dimethyl ether (PEGDM). | 12-31-2009 |
| 20100004156 | Small Compounds That Correct Protein Misfolding and Uses Thereof - The invention features compositions and methods that are useful for treating or preventing a protein conformation disease in a subject by correcting misfolded proteins in vivo. In addition, the invention provides compositions and methods that are useful for expressing a recombinant protein in a biochemically functional conformation. | 01-07-2010 |
| 20100004157 | PHARMACEUTICAL COMPOSITIONS FOR THE ORAL OR RECTAL ADMINISTRATION OF PROTEIN SUBSTANCES - Pharmaceutical compositions with differentiated, controlled and/or site-specific release are claimed for the oral or rectal administration of peptide or protein substances, including antibodies and soluble receptors capable of antagonising the pathogenetic role of several cell mediators such as interleukines, chemokines, growth factors, tissue necrosis factors, and interferons. Through the incorporation of the peptide or protein substance inside a controlled and/or site-specific release preparation, the application of this invention permits transporting the substances directly into the intestinal environment where a reduced quantity of proteolytic enzymes is present, a less aggressive microenvironment for the integrity of the protein structure and sequence. | 01-07-2010 |
| 20100009895 | METHOD FOR SELECTIVE LOCALIZATION OF ACTIVE AGENTS AT AND IN MITOCHONDRIA AND CORRESPONDING ACTIVE AGENTS - The present invention relates to novel methods for selective localization of active agents both at and in mitochondria within living cells, as well as corresponding active agents that penetrate through the cell membrane into the cells without further adjuvants and there can be localized both at and in mitochondria. These active agents are substituted with at least one monohydroxy mononitrophenyl rest or monohydroxy dinitrophenyl rest. | 01-14-2010 |
| 20100009896 | CAPTURE AGENTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Multi-ligand capture agents comprising two or more ligands are described, and related compositions, methods and systems. | 01-14-2010 |
| 20100009897 | POLYPEPTIDE HAVING LARVAE GROWTH INHIBITING OR INSECTICIDAL EFFECT ON SCARABAEIDAE INSECTS AND POLYNUCLEOTIDE ENCODING THE SAME - Through screening using an antibody to a polypeptide that constitutes a parasporal body in sporangia of | 01-14-2010 |
| 20100016207 | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid - The present invention provides methods of increasing the level or release of gamma aminobutyric acid (GABA) in the brain, treating Alzheimer's disease, Huntington's disease, symptoms thereof, anxiety, aggression, insomnia, cognitive or memory disturbances; seizures of any cause (e.g. idiopathic epilepsy), primary or metastatic brain tumors, depression (e.g. bipolar depression), or pain (e.g. neuropathic pain), comprising administration of glutamine, a salt thereof, or a glutamine-rich peptide. The present invention also provides methods for decreasing the level or release of GABA in the brain and treating hepatic encephalopathy, depressed consciousness, and coma, comprising decreasing dietary intake of glutamine. | 01-21-2010 |
| 20100016208 | PHOTOACTIVATABLE ANTIMICROBIAL AGENTS - Photoactivatable antimicrobial compounds and methods for the use thereof in the treatment of infections are provided. | 01-21-2010 |
| 20100016209 | Methods of Reducing Side Effects in Cancer Therapy - The present invention provides a method of decreasing side effects in a human or animal cancer patient due to radiation therapy or chemotherapy. With this method, methionine enkephalin is administered to the patient at least one time per week for a first time period, where the first time period is at least three weeks. In one embodiment, the first time period is one or two months. Methionine enkephalin is then administered to the patient one time per month for a second time period, where the second time period is at least one month, and where the second time period is consecutive to the first time period. In one embodiment, the total term of methionine enkephalin treatment is at least six months. Methionine enkephalin may be administered to the patient at the same time as, before, or after administration of radiation or chemotherapy. | 01-21-2010 |
| 20100016210 | Sensotherapy - The invention involves a preparation for the weight loss by means of appetite suppression and a method for administering the preparation to humans and other mammals. | 01-21-2010 |
| 20100016211 | Treatment of Melanoma With Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 01-21-2010 |
| 20100016212 | METHODS FOR TREATING PULMONARY HYPERTENSION AND COMPOSITIONS COMPRISING VASOACTIVE INTESTINAL PEPTIDE - A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity. or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can he delivered. A method for the treatment of cardiac arrest or pulmonary hypenension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention. | 01-21-2010 |
| 20100022438 | Method of separating carbon nanotubes - A method of separating carbon nanotubes having substantially the same diameter including the steps of: providing a sample of carbon nanotubes; separating individual nanotubes within the sample, and mixing with a solution comprising fibrous protein fibrils so that at least some individual nanotubes form a complex with the protein fibrils, and separating out those nanotubules which have formed a complex. Preferably the protein is collagen. The separated nanotubes can be used in the fields of electronics, medical and materials science. | 01-28-2010 |
| 20100022439 | Nanostructures with High Load of Active Agents - The present invention provides an improved method of loading silica nanostructures with an active agent, comprising exposing a mixture comprising a liquid medium containing an active agent and silica nanostructures to reduced air pressure for a time period, and then returning the mixture to atmospheric air pressure at the end of the time period. | 01-28-2010 |
| 20100022440 | VH4 Codon Signature For Multiple Sclerosis - The present invention provides for the diagnosis and prediction of multiple sclerosis (MS) in subject utilizing a unique a codon signature in VH4 expressing B cells that has now been associated with MS and not with any other autoimmune disease. | 01-28-2010 |
| 20100029542 | PROTEIN STERILISATION BY RADIATION AND ADDITION OF A STABILISING COMPOSITION - A method of sterilising a protein, comprises exposing to ionising radiation an at least substantially dry composition comprises a protein and a protective compound or combination of protective compounds having both of the following characteristics: (i) a rate of reaction with singlet oxygen greater than 1×10 7 L mol−1 S−1; (ii) being a reducing agent whilst at the same time containing a proton dissociable group with a pKa no more than 3 units from the pH of the composition. The compound having characteristic (i) is selected from histidine, thiamine and tryptophan, the compound having characteristic (ii) is selected from methionine, malate, citrate, lactate and tiron. The radiation is gamma radiation or electron beam, whereby the preferred dose is 15-40 kGy. | 02-04-2010 |
| 20100029543 | METHODS FOR TREATING NUCLEOSIDE-INDUCED PAIN - The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain. | 02-04-2010 |
| 20100035793 | Modulators - Use of a composition that modulates a STAT in the manufacture of a medicament for treating or preventing a fibroproliferative disease. The fibroproliferative disease may comprise keloid scarring. The composition may modulate one or more of; activity; phosphorylation; level of expression; or sub-cellular localisation of the STAT. The STAT may be STAT 3. | 02-11-2010 |
| 20100048450 | Sumoylation Control Agent and Uses Thereof - The present invention relates to novel agents that are useful for controlling sumoylation. In particular, the present invention relates to a sumoylation control agent comprising: (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof, or pharmaceutical composition thereof; or (ii) a compound or composition capable of modulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof. | 02-25-2010 |
| 20100048451 | NOVEL SPILL-RESISTANT FORMULATIONS COMPRISING HYDROCOLLOIDAL POLYMERS - The invention relates to novel spill resistant formulations comprising two or more hydrocolloidal polymers and an effective amount of a pharmaceutically active agent. The formulations have a viscometric yield value of a semi-solid, and a pH and spill-resistant consistency allowing for easier preparation and use of the pharmaceutical composition. | 02-25-2010 |
| 20100048452 | Injectable Sustained-Release Formulation Of Active Principles, And Process For The Preparation Thereof - Composition for the implementation of a therapeutic method for the human or animal body, comprising a fatty phase (O) and an aqueous phase (W), in the form of an 5 emulsion of the water-in-oil (W/O) type, in which said aqueous phase (W) comprises at least one hydrosoluble active ingredient, characterized in that said composition has a viscosity, measured at 25° C. in a 250-cm | 02-25-2010 |
| 20100056423 | Bacterial-Derived BLIS for Treatment of Acne - This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from | 03-04-2010 |
| 20100056424 | COSMETIC USE OF CHITINASE-TYPE PROTEINS - The present invention relates to the use, notably cosmetic and/or therapeutic, of the YKL-40 protein belonging to the family of chitinase-type proteins, of polypeptides derived from this protein or analogs thereof of a nucleic acid sequence encoding such a polypeptide or of an agent that modulates the activity or expression of such a polypeptide notably for stimulation of terminal epithelial differentiation. | 03-04-2010 |
| 20100062967 | COATED LIPID COMPLEXES AND THEIR USE - The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions. | 03-11-2010 |
| 20100062968 | Novel strategies for delivery of active agents using micelles and particles - The present invention provides biodegradable particles (e.g., three-dimensional particles) and micelles which can be used to encapsulate active agents for delivering to a subject. The present invention further provides methods for producing and delivering such particles and micelles. Additionally, the invention provides vaccination strategies that encompass the use of the novel particles and micelles. | 03-11-2010 |
| 20100062969 | HYDROPHILIC POLYMER-CONJUGATED LIPIDS FOR PEPTIDE AND PROTEIN FOLDING DISORDERS - The present invention provides a method of correcting peptide or protein misfolding, which can be used to treat peptide and protein disorder in a mammalian subject. The method comprises administering to the mammalian subject, preferably a human subject, an effective amount of a composition comprising sterically stabilized simple micelles (SSM) of a hydrophilic polymer-conjugated lipid or sterically stabilized mixed micelles (SSMM) of a hydrophilic polymer-conjugated lipid and a water-insoluble lipid. The composition may further comprise a biologically active compound, such as but not limited to vasoactive intestinal peptide (VIP), associated with the SSM or SSMM. | 03-11-2010 |
| 20100069288 | USE OF CYSTEINE-RICH WHEY DERIVED PROTEIN IN PATIENTS RECEIVING CHEMOTHERAPY OR RADIOTHERAPY TO IMPROVE PATIENT SURVIVAL - A cysteine-rich undenatured whey-derived protein formulation did not interfere with the tumor-cytotoxic effects of chemotherapy and radiation therapy and did not have a negative effect on the clinical outcome, that is, negatively affect survival and increase mortality. Indeed, use of a high-cysteine undenatured whey derived protein in the treatment of cancer patients resulted in an increase in patient survival. | 03-18-2010 |
| 20100069289 | ANIMAL FEEDS AND VETERINARY COMPOSITIONS - The present invention relates to an animal feed composition comprising protein from the family Fabaceae and protein from the family Asteraceae and to such formulations which also comprise glucan and/or mannan; such feeds finding utility in stabilising or increasing weight in a target animal, particularly fish, as well as in treating ectoparasitic infections, diarrhoea and bowel disease. | 03-18-2010 |
| 20100069290 | EJECTION LIQUID AND EJECTION METHOD - The ejection liquid of the present invention includes a compound having a guanidine group, and a carboxyl group or a sulfonic acid group in one molecule, and being represented by the general formula (1), or a salt of the compound, for the purpose of stably ejecting a solution including at least one of a protein and a peptide by imparting thermal energy to the solution. | 03-18-2010 |
| 20100069291 | COMBINATION COMPRISING CNDAC (2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYL-CYTOSINE) AND A CYTOTOXIC AGENT - A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N | 03-18-2010 |
| 20100075891 | Novel polynucleotides encoding polypeptides and methods using same - Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention. | 03-25-2010 |
| 20100075892 | Inhibition of SKP2-Cyclin a Interaction - Methods of killing a cancer cell are provided. Also provided are methods of treating a subject having a cancer. Additionally, compounds are provided that comprise a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1. Additionally provided are methods of screening an agent for the ability to kill a cancer cell. | 03-25-2010 |
| 20100075893 | PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR INCREASING BONE MINERAL DENSITY - The present invention relates to the use of a cocaine and amphetamine-regulated transcript (CART)-derived peptide for the preparation of a pharmaceutical composition for increasing bone mineral density by continuously providing elevated serum levels of the CART-derived peptide in a subject to be treated. Suitably, the elevated serum levels of the CART-derived peptide are continuously provided through slow release of the CART-derived peptide over an extended period of time from a slow release formulation. | 03-25-2010 |
| 20100087358 | NOTCH mutations leading to increased receptor signaling - The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients. | 04-08-2010 |
| 20100087359 | USE OF TRYPTOPHAN RICH PEPTIDES - The novel use of peptides derived from whey protein hydrolysate as active ingredient in a medicament or as food ingredient for elevating the cholescystokinin level in the blood, and for preventing or treatment of overweight and/or obesity, in an animal, including human, in need thereof. | 04-08-2010 |
| 20100093599 | SHINE CONTROL CLEANSER - This invention relates to shine control cleansing compositions, which are capable of controlling the appearance of oily and shiny skin for an extended period of time. | 04-15-2010 |
| 20100093600 | REGULATION OF NEUROTRANSMITTERS SEQUESTRATION AND RELEASE THROUGH MANIPULATION OF THE VESICULAR FUNCTIONS - A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises:
| 04-15-2010 |
| 20100093601 | COMPOSITIONS AND METHODS TO PROTECT CELLS BY BLOCKING ENTRY OF PATHOGEN PROTEINS - Pathogenic effector proteins which include one or more RxLR, dEER, Pexel or analogous motifs are blocked from entry into plant or animal cells by binding one or more of the motifs with a blocking compound which prevents binding of phosphoinositides or other polar lipids to the motifs which is a prerequisite for translocation of the pathogenic effector proteins into the plant or animal cell. The blocking compounds can take a variety of forms including synthetic peptides or the hydrophilic head-groups of phosphoinositides, phosphatidic acids, phospholipids, or sphingolipids. Suitable blocking compounds can be identified by assays demonstrating binding to RxLR, dEER, Pexel or analogous motifs. In addition, pathogenic effector proteins can be identified by analyzing whether they contain structural RxLR motifs using hidden markov modeling. | 04-15-2010 |
| 20100093602 | METHODS AND COMPOSITIONS FOR MODULATING ADHESION AND MIGRATION OF CADHERIN EXPRESSING CELLS - A method modulating adhesion and migration of at least one cadherin expressing cell includes administering a cadherin modulating agent to the at least one cadherin expressing cell in an amount effective to modulate cell adhesion and migration. The cadherin modulating agent includes a small molecule peptidomimetic of a peptide or cyclic peptide that comprises a cadherin cell adhesion recognition sequence. The cadherin modulating agent can promote or inhibit neurite outgrowth when applied to at least one neuron disposed on a substrate coated with a cadherin molecule. | 04-15-2010 |
| 20100099600 | CANDIDATES AGAINST INFECTION - The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model. | 04-22-2010 |
| 20100105601 | METHOD FOR TREATING A SYNUCLEINOPATHY - The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor. | 04-29-2010 |
| 20100105602 | TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS - The present invention relates to methods for treating intracellular bacterial infections with defensin polypeptides. | 04-29-2010 |
| 20100113326 | DIMERIC IAP INHIBITORS - Compounds made up of a homodimer or heterodimer having monomeric units of formula (I): wherein: each A is, independently, NR | 05-06-2010 |
| 20100113327 | METHODS FOR CONTROLLING MINERALIZATION OF EXTRACELLULAR MATRIX, THERAPEUTIC METHODS BASED THEREON AND MEDICAMENTS FOR USE THEREIN - The present invention relates to methods for selecting a candidate therapeutic agent for controlling mineralization of an extracellular matrix in a tissue of a subject. The invention further relates to a cell culture mineralization model comprising a culture of an extracellular matrix producing cell under conditions that support extracellular matrix formation and matrix maturation, a test compound, and means and methods for determining in expression levels of genes encoding matrix proteins. | 05-06-2010 |
| 20100113328 | Targeted delivery to legumain-expressing cells - The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells. | 05-06-2010 |
| 20100113329 | Maleamic Acid Polymer Derivatives and Their Bioconjugates - The present invention is directed to maleamic acid derivatives of water soluble polymers, to chemically stable water-soluble polymer succinamic acid-active agent conjugates, and to methods for reproducibly preparing, characterizing and using such polymer reagents and their conjugates. | 05-06-2010 |
| 20100130401 | PROTEIN HYDROLYSATE AND PLANT STEROL CONTAINING COMPOSITION FOR IMPROVING SERUM LIPID PROFILE AND PREVENTING ATHEROSCLERORIS - The invention relates to a terapeutical composition comprising a protein hydrolysate and a plant sterol, wherein the weight ratio of the plant sterol to the protein hydrolysate is from 1:0.02 to 1:150. The invention also relates to a terapeutical composition comprising a protein hydrolysate and a synthetic emulsifier and/or a lipid based grain fraction having emulsifying properties. Said compositions can be used in a pharmaceutical, nutraceutical or food product for improving serum lipid profile. | 05-27-2010 |
| 20100137186 | USE OF AN ACTIVE PRINCIPLE ORIGINATING FROM AMARANTH (AMARANTHUS) FOR PREPARING A COMPOSITION INTENDED TO ACTIVATE CELLULAR ENERGY AND TO PROTECT THE SKIN FROM OXIDATIVE DAMAGE - Methods of administering in a cosmetic composition or a pharmaceutical composition, an effective amount of a peptide active principle originating from amaranth of the species | 06-03-2010 |
| 20100137187 | Glutamate-Enhanced Cell-Penetrating Peptides and Methods of Using Same - Disclosed herein are novel glutamate-enhanced cell-penetrating peptides (CPPs) for use as delivery vehicles to mediate intracellular uptake of therapeutic payloads and methods of using the same. | 06-03-2010 |
| 20100144587 | Frequency modulated drug delivery (FMDD) - Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties. | 06-10-2010 |
| 20100144588 | PROTON ACCEPTOR IMINIUM/CARBOCATION-TYPE COUPLING AGENTS - Novel iminium-type coupling agents containing proton acceptors in their iminium moiety, which can be used beneficially as coupling agents in various chemical polypeptide and/or polynucleotide syntheses, and are particularly useful as yield enhancing and racemization suppressing coupling agents for use in peptide syntheses, are disclosed. Further disclosed are a process of preparing such iminium-type coupling agents and their use in the preparation of polypeptides and/or polynucleotides. | 06-10-2010 |
| 20100144589 | METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTS - The present invention provides methods of predicting the relative growth rate, replication rate, or lethality of a first malignancy as compared to another malignancy or as compared to a plurality of malignancies, including methods of predicting the relative growth rate, replication rate, or relative lethality of a primary malignancy as compared to a metastatic malignancy, including comparing the concentration of Replikin sequences in the first malignancy with the concentration of Replikin sequences in another malignancy or malignancies and further provides Replikin peptides and Replikin Peak Genes identified within a malignancy for diagnostic, therapeutic, preventive, and predictive purposes. | 06-10-2010 |
| 20100144590 | BIOCOMPATIBLE PHASE INVERTABLE PROTEINACEOUS COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME - Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a proteinaceous substrate and a crosslinking agent, such as a stabilized aldehyde crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications. | 06-10-2010 |
| 20100152095 | Wound healing - A composition for use in the treatment of wounds to inhibit scar tissue formation during healing is disclosed, comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier. The method of preparation of said composition and method of administering the composition to a host suffering from tissue wounding is also disclosed. | 06-17-2010 |
| 20100152096 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF AMINO-SUBSTITUTED (E)-2, 6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES - Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. | 06-17-2010 |
| 20100152097 | POLYMER-BASED SUSTAINED RELEASE DEVICE - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 06-17-2010 |
| 20100160207 | Feedback Prodrug - Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme. | 06-24-2010 |
| 20100160208 | Pharmaceutical composition - The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and/or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormone. | 06-24-2010 |
| 20100167979 | RHEUMATOID ARTHRITIS-PREVENTIVE AGENT FOR ORAL INTAKE - There is provided a rheumatoid arthritis inhibitor for oral intake that has an inhibitory effect on rheumatoid arthritis and is excellent in safety. The rheumatoid arthritis inhibitor for oral intake of the present invention contains, as an active component, a casein hydrolysate containing free amino acids and peptides obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, or a mixture of free amino acids and peptides contained in the hydrolysate. | 07-01-2010 |
| 20100167980 | Prolyl Endopeptidase Inhibitors For Reducing or Preventing Neutrophilic Inflammation - Provided herein are methods for reducing or preventing neutrophilic inflammation in a subject comprising selecting a subject with or at risk for neutrophilic inflammation and administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase. Provided herein are also methods for treatment or prevention of diseases associated with neutrophilic inflammation. | 07-01-2010 |
| 20100167981 | Encapsidation of Heterologous Entities into Virus-Like Particles - Methods are provided for the utilization of bacterial cell-free extracts in the synthesis of high yields of virus like particles with encapsidated cargo. | 07-01-2010 |
| 20100167982 | BARRIER INTEGRITY IN HIV PATIENTS - The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides. | 07-01-2010 |
| 20100167983 | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 07-01-2010 |
| 20100173822 | COMPOSITION COMPRISING SACCARIDES & PEPTIDES & USES THEREOF - The present invention relates to a composition comprising saccharides and peptides in unique proportion for improving the endurance capability of the human body in motion, promoting recovery after motion, reducing body fat, and alleviating fatigue of central nerves during motion. The composition can further comprise vitamins, minerals, flavoring materials and electrolytes. The composition can be a liquid beverage, a solid beverage, a food additive or an energy bar. | 07-08-2010 |
| 20100173823 | ALPHA2C ADRENORECEPTOR AGONISTS - In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions. | 07-08-2010 |
| 20100179089 | Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly - Compositions and methods for managing inflammation in the elderly by delivering a selection of amino acids, including arginine and/or citrulline, in a synergistic ratio with omega-3 fatty acids and carbohydrates with a low glycemic index. | 07-15-2010 |
| 20100184636 | Method of Regulating Mammalian Target-of-Rapamycin Activity by Interaction Between Phospholipase D and Raptor - The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR. | 07-22-2010 |
| 20100184637 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING AN ACTIVE ANTIOXYDANT PRINCIPLE AND CELL ENERGY ACTIVATOR - A cosmetic or pharmaceutical composition, and particularly dermatological composition, comprising, in a physiologically adapted medium, as active principle, polypeptides or peptides, and methods of administering a composition capable of increasing cell energy and to protect the skin from oxidative damage. Also, a cosmetic treatment procedure aimed at protecting the skin and the skin appendages from external aggressions and to combat skin aging. | 07-22-2010 |
| 20100184638 | Galanin Receptors and Brain Injury - There is provided the use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain injury, damage or disease, wherein the brain injury or damage is caused by one of: embolic, thrombotic or haem-orrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renai dialysis; reperfusion brain damage following myocardial infarction; brain disease; chemical damage as the result of excess alcohol consumption or administration of chemotherapy agents for cancer treatment; radiation damage; or immunological damage as the result of bacterial or virai infection. The brain disease may be one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease. | 07-22-2010 |
| 20100184639 | NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC OF THE NEISSERIA GENUS PATHOGENIC STRAINS - The invention concerns nucleic acids coding for polypeptides specific of the | 07-22-2010 |
| 20100190684 | INHIBITION OF PALMITOYL ACYL TRANSFERASE EXPRESSION AND/OR ACTIVITY FOR THE REGULATION OF ANTIPROLIFERATIVE FACTOR ACTIVITY - The invention generally concerns inhibition of a molecule that has a role in post-translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ZDHHC2 expression results in modulation of APF receptor activity, and in specific aspects such modulation is therapeutic and/or preventative for a bladder condition, such as interstitial cystitis. In addition, inhibition of CKAP4 palmitoylation in certain cases also decreases its activity as a tPA receptor on smooth muscle cells or surfactant A on type II pneumocytes, and/or generally inhibits its function as a cell membrane receptor, cell chaperone molecule, and/or membrane trafficking agent. | 07-29-2010 |
| 20100190685 | PROGNOSTIC FACTOR IN SARCOMA, AND METASTASIS INHIBITOR - The present invention relates to uses of sarcopodin as a gene associated with distant metastasis or prognosis for survival in tumors. Specifically, the present invention provides a method of determining the risk of distant metastasis or prognosis for survival in a tumor, comprising measuring the expression level of sarcopodin in a tumor tissue. Furthermore, the present invention provides an agent for inhibiting metastasis containing a polynucleotide complementary to an mRNA that encodes sarcopodin or an expression vector capable of expressing the polynucleotide. | 07-29-2010 |
| 20100197561 | Biomarkers for Ovarian Cancer: B2 Microglobulin - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry. | 08-05-2010 |
| 20100197562 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS - In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ÿ2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ÿ2C adrenergic receptors using such compounds or pharmaceutical compositions. | 08-05-2010 |
| 20100197563 | COMPOSITIONS AND METHODS FOR ALTERING ELASTOGENESIS - Compositions and methods are provided for promoting elastin fiber formation (elastogenesis) in a cell, including methods that comprise contacting a cell that is capable of elastogenesis with (i) a mutated biglycan polypeptide that lacks chondroitin sulphate proteoglycan chains, (ii) a versican V3 isoform polypeptide that lacks most or all of the polypeptide regions encoded by one or more of exons 4, 5 or 6 or by exons 9-10 or 11-13, and/or with (iii) metastatin. | 08-05-2010 |
| 20100204085 | STRUCTURE-BASED DESIGN OF PEPTIDE INHIBITORS OF AMYLOID FIBRILLATION - The invention provides methods for designing peptides that inhibit aggregation in target polypeptides. The candidate inhibitory peptidic compounds have an oligomeric sequence that forms energetically-favorable interactions with the amino acid sequence of the steric zipper region of the target protein, and also possess a zipper-disrupting feature that disrupt the peptide stacking at the steric zipper region. This method can be used to obtain inhibitory peptides to disrupt fibril formation involving any protein for which a steric zipper sequence can be identified. The invention also provides inhibitory peptidic compounds, which can be used in pharmaceutical compositions and methods for treating polypeptide aggregation-associated diseases or conditions. | 08-12-2010 |
| 20100204086 | BONE MORPHOGENIC PROTEINS (BMP), BMP RECEPTORS AND BMP BINDING PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF GLAUCOMA - The present invention provides methods and kits for diagnosing and treating glaucoma. | 08-12-2010 |
| 20100210504 | ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes (at physiologic pH, but can become active toward cell membranes if the environment is acidified below ca. pH 6.8), coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophereis can also be used with the disrupting agents. | 08-19-2010 |
| 20100216688 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides. | 08-26-2010 |
| 20100216689 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST - Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease. | 08-26-2010 |
| 20100222250 | POLY-BETA-PEPTIDES FROM FUNCTIONALIZED BETA-LACTAM MONOMERS AND ANTIBACTERIAL COMPOSITIONS CONTAINING SAME - Disclosed is a method of making β-polypeptides. The method includes polymerizing β-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product β-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS) | 09-02-2010 |
| 20100227791 | Compounds Having Antitumor Activity - Disclosed is the use of compounds of formula (I) | 09-09-2010 |
| 20100227792 | PHOSPHOLIPID AND PROTEIN TABLETS - A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared. | 09-09-2010 |
| 20100227793 | Compositions and Methods for Treating Amyotrophic Lateral Sclerosis - The invention relates to methods for preserving fast axonal transport in a cell affected by Amyotrophic Lateral Sclerosis by inhibiting pathogenic superoxide dismutase-induced increases in p38α activity. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin-1, as well as methods for monitoring treatment of Amyotrophic Lateral Sclerosis based on the phosphorylation of p38a, neurofilament heavy chain subunits, and serines 175 and/or 176 of kinesin-1. | 09-09-2010 |
| 20100227794 | SMART CONTRAST AGENT AND METHOD FOR DETECTING TRANSITION METAL IONS AND TREATING RELATED DISORDERS - The present disclosure provides smart contrast agents for transition metals and a method of using the same. The smart contrast agents include a core peptide and a first labeling group attached to a first end of the core peptide. The smart contrast agents can also include a second labeling group attached to a second end of the core peptide. The core peptide can bind to transition metals, and can be homologous to a fragment selected from the extended octarepeat region of a prion protein. | 09-09-2010 |
| 20100234272 | Processes for Preparing a Polypeptide - The present invention relates to an improved process for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate, and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate. The process comprises: (a) polymerizing a mixture of N-carboxyanhydride of L-tyrosine, N-carboxyanhydride of L-alanine, N-carboxyanhydride of a protected L-glutamate and N-carboxyanhydride of a protected L-lysine, in a polar aprotic solvent in the presence of an initiator, to form a protected polypeptide; (b) admixing an acid with the protected polypeptide formed in Step (a) and a solvent, to form a product; and (c) admixing a substance selected from the group consisting of an alkali or alkaline earth metal hydroxide, a carbonate, a hydrogencarbonate, and mixtures thereof, with the product formed in Step (b), and a solvent or a mixture of a solvent and water, to form a deprotected polypeptide or a pharmaceutically acceptable salt thereof. | 09-16-2010 |
| 20100240575 | ANTI-OBESE IMMUNOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESE VACCINE COMPOSITION COMPRISING THE SAME - Disclosed is an immunogenic hybrid polypeptide comprising a mimetic peptide of a B cell epitope of apolipoprotein B-100 and helper T cell epitope, the mimetic peptide being fused at its C-terminus to an N-terminus of the helper T cell epitope. Also disclosed is a vaccine composition for preventing or treating obesity comprising the polypeptide. | 09-23-2010 |
| 20100240576 | ANTICONVULSANT COMBINATION THERAPY - The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures. | 09-23-2010 |
